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ABSTRACT

THE APPLICATION OF MELATONIN AND PLATELET-RICH PLASMA IN THE
DEVELOPMENT OF A BIOACTIVE CALCIUM ALUMINATE BONE
REGENERATIVE SCAFFOLD

By
William P. Clafshenkel
July 2011

Dissertation supervised by Paula A. Witt-Enderby, Ph.D.
Over 500,000 bone graft procedures are conducted annually within the United
States. Autografts contribute to donor site complications and disease transmission with
allografts has been described. Many ceramics are only osteoconductive and are brittle,
limiting their clinical use. Thus, the objective of this study was to create a bone
substitute with osteoinductive properties similar to natural bone using the ceramic
biomaterial calcium aluminate (CA). Calcium aluminate materials are durable and
remain moldable for an extended period of time at room temperature. Further, the
surfaces of CA scaffolds can be modified with biological agents through simple chemical
means to locally deliver agents directly to sites of injury. In order to enhance local bone
regenerating characteristics of CA scaffolds, melatonin and platelet-rich plasma (PRP)
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were utilized for their known osteoinductive properties. Platelet-rich plasma enhances
soft and hard tissue formation primarily through growth factor-mediated signaling
pathways. Melatonin augments osteoblast differentiation and inhibits osteoclastmediated bone resorption through receptor-dependent signaling and free radical
scavenging activity, respectively. Thus, it was hypothesized that melatonin and/or PRP
would provide osteoinductive properties to CA scaffolds to promote bone regeneration in
a rodent model of critical-size calvaria defects. Modified CA scaffolds (CA-Mel) were
produced by immobilizing melatonin to the CA surface through a covalent linkage. The
biocompatibility of unmodified and modified CA scaffolds was initially tested in vitro
and indicated that modified surfaces had a preference for the adhesion and proliferation
of normal human osteoblasts versus NIH 3T3 fibroblasts. Moreover, the immobilization
of melatonin to the CA surface may delay the differentiation of human adult
mesenchymal stem cells (hAMSCs) and may have facilitated their migration across the
CA surface. Two-month-old ovariectomized rats were randomized into implant groups
receiving unmodified or modified scaffolds in the absence (CA and CA-Mel) or presence
of PRP (CA+PRP and CA-Mel+PRP). Histological sections confirmed that both CA
scaffold types were well-tolerated and provided evidence of tissue infiltration and
scaffold biodegradation over time. Bone regeneration in animals was assessed by
fluorochrome labeling at three and six months. While there was a lack of synergism
between melatonin and PRP in the CA-Mel+PRP group, animals implanted with CA-Mel
showed the greatest intensity and abundance of bone remodeling at both time points
compared to all other groups. Radiographic data indicated a significant increase in the
density of newly formed bone over time in all groups. The absence of a detectable
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decrease in density suggests that the modest biodegradation of CA scaffolds is balanced
with processes of bone formation. Finally, both unmodified and modified CA scaffolds
continued to provide a supportive surface for bone formation out to six months. Overall,
results from this study suggest that CA scaffolds modified with melatonin may enhance
bone remodeling activity in calvarial defects through hAMSC differentiation and
recruitment and by preferentially supporting the viability and function of mature
osteoblasts. This novel bioactive ceramic scaffold has the potential to change the dogma
of bone grafting in fields like dentistry and reconstructive surgery. Continued
optimization of this therapy is warranted and the attachment of other osteoinductive
biomolecules is being considered.
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INTRODUCTION
Skeletal Development and Remodeling
Much of the appendicular skeleton is comprised of long bones such as the
clavicles, humeri, radii, unlnae, femurs, tibiae, fibulae, and phalanges (1). Flat bones
include the skull, mandible, scapulae, sternum, and ribs (1). Overall, the adult human
skeleton is approximately 80% cortical (compact) bone and 20% trabecular (spongy)
bone (1). Bone is a dynamic tissue that undergoes growth, modeling, and remodeling
throughout the lifetime of an individual. Bone growth occurs through longitudinal and
radial growth during childhood and adolescence (1). Bone modeling is the mechanism by
which bone changes its overall shape in response to physiological influences or
mechanical forces (1). Modeling leads to gradual adjustments of the skeleton to these
forces. Bone remodeling is a process by which bone is renewed to maintain bone
strength and mineral homeostasis (1).
Bone remodeling requires the recruitment and activity of several key cell types
and follows a chronological progression through four sequential phases (Fig. 1). The first
of these phases is activation (Fig. 1A). Given that osteoclast precursors are of
hematopoietic origin, they are recruited from the circulation and fuse to the exposed bone
surface via interactions between integrin receptors on their cell membrane and matrix
peptides on the bone surface (1, 2). Once fused to the exposed bone surface, osteoclast
precursors transition into mature osteoclasts. Mature osteoclasts are responsible for the
removal of surface bone.
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Osteoclast-mediated bone resorption follows the activation phase and can last two
to four weeks during each remodeling cycle (1) (Fig. 1B). Osteoclast activity is regulated
by specific biomolecules and cytokines including receptor activator of nuclear factor
kappa B (NFκB) ligand (RANKL), osteoprotegrin (OPG), interleukin-1 (IL-1), IL-6,
parathyroid hormone, vitamin D, and calcitonin (1) (Fig. 2). Many of these resorption
activators increase the production of RANKL, which when bound to its receptor, RANK,
on osteoclast progenitor cells, causes an increase in osteoclast production and function
(3). Mature osteoclasts form an enclosed environment around the region to be remodeled
via interaction with adhesion proteins such as integrins and vitronectin (3). Mobilization
of bone mineral is aided by osteoclast secretion of hydrogen ions via H+-ATPase proton
pumps and chloride channels to lower the pH of the resorbing environment and by direct
digestion of the organic matrix (1). Osteoclasts also secrete proteases like cathepsin K
and metalloproteinases that act to enzymatically break down collagen and other bone
matrix proteins (3). The result of osteoclast activity is a resorption pit, a small burrow of
resorbed bone beneath the sealed region.
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Figure 1. Phase of Normal Bone Remodeling
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Figure created by William P. Clafshenkel.

The third phase is the reversal phase whereby bone resorption transitions to bone
formation (Fig. 1C). Bone formation is dependent on the activity of bone-forming cells
3

called osteoblasts derived from mesenchymal stem cells residing in the bone marrow and
periosteum (4, 5). Osteoblast activity in exchange for osteoclast activity is highlycoupled through signaling events that are poorly understood. Proposed signaling
molecules that regulate the coupling of these signals include transforming growth factorβ (TGF- β), insulin growth factor-1 (IGF-1), IGF-2, bone morphogenetic proteins
(BMPs), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) (1)
(Fig. 2). In fact, TGF-β and IGF-2 are the first and second most abundant mitogens in
human bone extracellular matrix (6). TGF-β is a member of a family of polypeptide
growth regulators that affect cell growth and differentiation during both developmental
processes and tissue repair (6). It is present in the extracellular matrix as a latent
component but is released and activated through increased bone resorption, where it is
free to stimulate chondrogenesis (i.e., the development of hyaline cartilage) and
osteogenesis (i.e., the development of new bone) (6). IGFs function to stimulate
osteoblast proliferation and matrix synthesis (6). Moreover, osteoblasts synthesize
osteoprotegrin (OPG), a known regulator of osteoclast activity and thus, bone resorption
(7). In the absence of OPG, RANK ligand (RANKL) on the surface of osteoblasts is free
to interact with RANK on the osteoclasts precursors and osteoclasts, thereby coupling
osteoclast formation and activity with that of osteoblasts (7). However, this coupling
event is blocked in the presence of OPG, which acts as a decoy receptor for RANKL.
Blocking RANKL binding to RANK can result in the down-regulated transcription of
osteoclastogenic genes in osteoclast precursors or the down-regulation of resorption
activity of mature osteoclasts (7).
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Figure 2. Signaling Events that Regulate and Couple Osteoblast and Osteoclast Activity
(+) BMPs, TGFβ, IGFs, FGF
BONE MATRIX SYNTHESIS
RANKL

PTH

(+)

(+)

RANK
Osteoblast

PTH (-)

OCPC

(-)

(+) IL-6
DIFFERENTIATION

APOPTOSIS

Osteoclast
OPG
Bone Matrix

Figure 2. Osteoblast and osteoclast activities are highly regulated and coupled by hormones,
cytokines, growth factors, and secreted proteins. Parathyroid hormone (PTH) stimulates bone
remodeling by promoting the production of RANKL by osteoblasts. Additionally, PTH inhibits the
apoptosis of osteoblasts and osteocytes. Receptor activator of NF-κB ligand (RANKL) is
produced by osteoblasts and couples their interaction with osteoclast precursors (OCPC) to
promote differentiation into mature osteoclasts. Osteoblasts also secrete osteoprotegrin (OPG),
which acts as a decoy receptor for RANKL and reduces osteoclast formation and activity.
Interleukin-6 (IL-6) is a positive regulator of OCPC differentiation and activity. Lastly, osteoclastmediated bone resorption releases embedded growth factors from the bone matrix. These
include bone morphogenetic proteins (BMPs), transforming growth factor-β (TGFβ), insulin-like
growth factors (IGFs), and fibroblast growth factor (FGF). These growth factors promote the
production of bone matrix by osteoblasts. Figure created by William P. Clafshenkel.

The final phase, bone formation, can last approximately four to six months (Fig.
1D). Bone formation in the adult skeleton involves intramembranous bone formation and
endochondral bone formation. The growth of long bones occurs by the conversion of
cartilage into calcified bone, a process called endochondral ossification. During
endochondral bone formation, mesenchymal stem cells differentiate into chondroblasts
that synthesize a cartilage template that is later vascularized and replaced by mineralized
bone (3). Intramembranous ossification differs from endochondral ossification in that
there is no cartilage intermediate; mesenchymal stem cells differentiate directly into
bone-forming osteoblasts (3). Intramembranous ossification is important for the
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development of the cranial flat bones, the periosteal collar of long bones, and for fracture
healing (3). During this time, osteoblast secrete new collagenous organic matrix that is
subsequently mineralized through the concentration of calcium and phosphate (1). At the
completion of the bone formation phase some osteoblasts will be embedded in the
secreted bone matrix and become osteocytes, while others will become lining cells at the
bone surface (1). Lining-cells have the capacity to redifferentiate into osteoblasts when
exposed to parathyroid hormone or mechanical forces (1). Osteocytes form cell networks
within the bone and can transduce mechanical stimuli from the periphery to the center of
the bone (3).

Spectrum of Skeletal Disorders: Pathological, Congenital, and Acquired Bone Loss
Adult rates of bone remodeling (2-3%) are relatively low compared to those of
childhood and adolescence, but are necessary to maintain the biomechanical strength of
bone (1). Nonetheless, several factors can impact the rate of bone remodeling in the adult
human. Some of these can lead to the bone disease called osteoporosis, a condition
where bone remodeling is imbalanced. Specifically, the activity of osteoblasts is outweighed by that of osteoclasts resulting in a net loss of bone during bone remodeling that
can lead to reductions in bone strength and alterations to bone microarchitecture (2, 3).
Risk factors for osteoporosis range from lifestyle habits, to disease states, to the use of
certain medications. Physical conditions that increase a person’s risk of developing
osteoporosis include a low body weight, a small body frame, older age, a low bone
mineral density, a low peak bone mass at maturity, surgically induced menopause, and
estrogen deficiency (8, 9). Several disease states including diabetes type 1, adrenal
insufficiency, inflammatory bowel disease, and others can increase osteoporosis risk (8,
6

9). Likewise, medications such as oral glucocorticoids can further increase the risk of
developing osteoporosis (9). Lifestyle habits that contribute to osteoporosis and
osteoporosis-related fractures include cigarette smoking, immobility, low physical
activity, alcohol consumption, a diet low in calcium and vitamin D, and nightshift work
(8-10). Osteoporosis is a global disease that affects many bones of the body including
long bones, the spine, and bones of the jaw. The prevalence of osteoporosis-related
fractures is predicted to increase from about 10 million to greater than 14 million by 2020
(11). Both men and women are susceptible to osteoporosis, although its prevalence
among women is greater (11). Women 65 years and older account for approximately
74% of all fractures, while men the same age account for approximately 61% (estimates
from 2005) (11).
Other skeletal disorders involving alterations to the normal rates of resorption and
formation of bone and cartilage include osteoarthritis, rheumatoid arthritis, and bone
disease associated with cancer. In osteoarthritis, articular cartilage is degraded giving
way to hypertrophy of the subchondral bone (3). Rheumatoid arthritis is characterized by
the destruction of articular cartilage and excessive resorption of the subchondral bone (3).
Cancer metastases traveling through the blood stream can lead to the development of
secondary tumors on bone surfaces. Focal cancer metastases on the bone can either cause
abnormal bone formation (osteoblastic or osteosclerotic lesions) or bone breakdown
(osteolytic lesion) (3). In both cases, the bone of the lesions is very weak and susceptible
to fracture.
Bone abnormalities not only occur with lifestyle habits, aging, and disease states
but can also occur with major trauma such as fractures or with congenital malformations.
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Specifically, bone defects in the craniomaxillofacial skeleton remain a major and
challenging health concern (12). These defects can occur as a result of congenital
malformations or acquired injuries. For example, in 2001, approximately 38,000 children
underwent surgery to repair birth defects, while approximately 24,000 underwent
maxillofacial surgeries for injuries to the face and jaw (12). Wars in Iraq and
Afghanistan have contributed to the largest incidence of head trauma since the Vietnam
conflict (12). Moreover, large orthopedic defects, in which the natural regenerative
capacity of the bone is exceeded, rely on the application of mechanically and biologically
optimized biomaterials to facilitate healing (13).

Treatment Options for Bone Loss
The treatment of osteoporosis has long been investigated and many current
therapies available on the market target bone changes associated with the progression of
the disease. The majority of osteoporosis medications are antiresorptive agents aimed at
mitigating bone loss by decreasing osteoclast activity. Antiresorptive agents include the
bisphosphonates (alendronate [FOSAMAX], risedronate [ACTONEL], ibandronate
[BONIVA], and zoledronic acid [RECLAST]), selective estrogen receptor modulators
(SERMs) (raloxifene [EVISTA]), and more recently, a RANK ligand inhibitor
(denosumab [PROLIA]) (14).
Bisphosphonates have been utilized for a wide spectrum of bone disorders
including glucocorticoid-induced osteoporosis, Paget’s disease, and the treatment of
hypercalcemia related to bone malignancy (3). Although reportedly effective at slowing
bone loss, clinicians report the incidence of osteonecrosis, or degradation, of the jaw
8

(ONJ) is increasing among menopausal patients utilizing oral bisphosphonates for the
prevention and treatment of osteoporosis (15, 16). Based on cases reported in the
literature, the incidence of ONJ induced by oral bisphosphonate therapy is estimated to be
between 2.5% to 27.3% (17). Although the exact pathology is unknown, it is theorized
that oral bisphosphonate-induced ONJ is attributed to the accumulation of
bisphosphonates in areas of elevated bone remodeling, due to their high affinity for
calcium, their limited metabolism, and their down-regulation of bone turnover (16, 17).
Symptoms of ONJ include pain, swelling, exposed bone, and purulent secretions (17).
ONJ further reduces the already limited quantity and quality of bone in the oral cavity of
menopausal females, and can significantly prolong healing time after oral surgery.
Consequently, the results of oral procedures sought to repair and/or replace jaw bone and
missing teeth are often unsuccessful (18). Further, oral bisphosphonate use has the
potential to increase the risk of low-energy subtrochanteric or diaphyseal femur fractures
(19) and the accumulation of bone microdamage with treatment over time (20). This is
most likely attributed to the continued catabolic nature of these antiresorptive agents on
bone. From a structural point of view, the backbone of bisphosphonates is analogous to
pyrophosphates (P-O-P), where a carbon atom replaces the oxygen atom. The functional
differences between bisphosphonate species is related to side chain substitutions and the
presence or absence of nitrogen (3, 21). Bisphosphonates embedded in the bone matrix
enter into osteoclasts during bone resorption. Non-nitrogen-containing bisphosphonates
are incorporated with adenosine monophosphate (AMP) to form non-hydrolyzable ATP
analogs (21). These analogs are functionally inactive and their accumulation induces
osteoclast apoptosis (21). Nitrogen-containing bisphosphonates inhibit farnesyl
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pyrophosphate (FPP) synthase, the enzyme responsible for the generation of prenylated
proteins that are required for osteoclast function and survival (21). It is thought that this
inhibition induces osteoclast apoptosis via caspase activation pathways (21) (Fig. 3).
Figure 3. Mechanism of Action of Bisphosphonates on Osteoclasts
Simple BPs

Nitrogen-containing BPs
HMG CoA

AMP

BP

Mevalonate
AMP-BP

BP-containing
ATP analog

Intracellular
Accumulation

NBP

APOPTOSIS
FPP Synthase
Caspase
Activation

FPP

GGPP

Active Osteoclast
Farnesylated or Geranylgeranylated
Proteins
BP

NBP

BP

Bone / Resorption Pit
Figure 3. Simple (BP) and nitrogen-containing (NBP) bisphosphonates bound to bone mineral
are internalized into osteoclasts during bone resorption. Simple bisphosphonates (e.g.,
etidrondate, DIDRONEL) are incorporated into non-hydrolyzable ATP analogs. The accumulation
of such non-functional ATP species induces osteoclast apoptosis. Nitrogen-containing
bisphosphonates (e.g., alendronate, FOSAMAX) inhibit farnesyl diphosphate (FPP) synthase
disrupting the synthesis of FPP and geranylgeranyl diphosphate (GGPP) and their prenylated
forms. NBP-induced apoptosis is thought to occur via the activation of caspase pathways. AMP
= adenosine monophosphate. HMG CoA = 3-hydroxy-3-methyl-glutaryl Co-enzyme A; initial
substrate for the mevalonate pathway. Figure created by William P. Clafshenkel.

Selective estrogen receptor modulators like raloxifene have been shown to reduce
the incidence of vertebral fractures, although the increase in bone mineral density (BMD)
is relatively modest (3). Likewise, SERMs are not without untoward effects. The
activity of SERMs as agonists or antagonists is tissue specific, and while they maintain
the beneficial effects of estrogen on bone, they can produce host flashes, vaginal dryness,
10

and increases the risk of thromboembolism (22, 23). Their mechanism of action is
related to their unique ability to induce conformation changes in the estrogen receptor,
which results in the recruitment of different combinations of co-activators or corepressors (3). It is hypothesized that the availability of co-regulators represents the basis
for their tissue-selective pharmacology (3).
Only the PTH analog, teriparatide [FORTEO] has been commercially developed
for osteoporosis patients in an effort to rebuild new bone. Teriparatide has been shown to
increase bone mass, increase bone density, and improve the microarchitecture of bone
(14). It is thought that PTH accomplishes this by promoting the proliferation and
differentiation of osteoblasts and osteocytes, while inhibiting their destruction by
apoptosis (3). Mechanisms underlying PTH-induced osteoblast survival may include
activation of cAMP response element binding protein (CREB)-mediated transcription of
survival genes through G-coupled protein receptor pathways (24). Despite beneficial
effects on the bone, the need for daily subcutaneous injections affects patient compliance
(14) and its use is limited to a two-year duration (25). While medications can slow the
progression of osteoporosis, many patients are still at increased risk for the development
of fractures. Osteoporosis-related fractures contribute to a significant amount of
economic expense through costly procedures, extended hospital stays, and prolonged
rehabilitation.
The treatment of large bone defects remains a challenge as well. The current
procedures for the restoration or replacement of bone for congenital or acquired bone
defects often results in poor aesthetic and functional outcomes (12). Human bone
morphogenetic protein 2 (BMP-2; [INFUSE]) has been used clinically for certain
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interbody spinal fusions, open tibial fractures, and maxillofacial procedures (12, 26);
however, instances of ectopic bone formation and uncontrolled bone growth have been
described with higher doses (27). Interest is increasing in other recombinant forms of
BMP family members, namely rhBMP-7 and rhBMP-4, albeit this research has been
exclusive to animal models (27). Current research efforts seek to improve bone
regeneration through the development of new surgical techniques or bone graft therapies.

Autologous, Allogenic, and Synthetic Bone Grafts
Bone restoration for osteoporosis-related fractures and bone replacement for
larger bone defects have benefited from developments in bone grafting procedures. Over
500,000 bone grafting procedures are conducted annually within the United States, with
2.2 million occurring worldwide (28). Bone graft procedures have been used to repair
bone defects in a variety of fields including orthopedics, neurosurgery, and dentistry.
Ideally, bone grafts from either autogenic, allogenic, or synthetic sources would replicate
the normal bone healing responses of autogenous bone by providing osteogenic,
osteoinductive, and osteoconductive activity. An osteogenic graft would contain living
cells that are capable of differentiating into bone (29). The osteoinductive, or
stimulatory, effects of the graft material on local or transplanted cells would facilitate the
differentiation of stem cells into osteoblasts or promote osteoblast activity (29). Lastly,
osteoconductive properties of the graft material would provide a suitable surface for the
apposition of newly formed bone (29, 30). The combination of osteoconductive and
osteoinductive properties would allow the implanted graft to integrate into the newly
formed bone, defined as osteointegration (31).
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Although the bone autograft is considered to be the “gold standard” for bone graft
procedures, its use has been associated with 8-20% of donor site complications including
donor site hematoma, soft tissue breakdown, pain, and a lengthened hospital stay (28,
32). Moreover, the use of bone autografts in osteoporotic populations is usually
contraindicated given a significant reduction in the quality and quantity of available bone
(18). Although the prevalence of the bone allograft is slowly increasing, the risk of
disease transmission has been described (28). Additionally, the chemical processing of
bone allografts to remove cells and bioactive proteins in an effort to reduce
immunogenicity weakens the mechanical integrity of the graft (28). The use of allografts
is also limited to the volume of material readily available at most institutions (33).
There has been significant impetus in researching and developing an ideal
synthetic bone substitute for a wide array of bone grafting procedures in an effort to
circumvent the issues with bone autografts and allografts as described above. The
research, development, and use of several biomaterials has spanned the better part of six
generations and can be loosely divided into three evolutionary categories: bioinert
materials, bioactive and biodegradable materials, and materials designed to stimulate
specific host cellular responses through dynamic molecular signaling (34). Despite the
conceptual transition of biomaterial development, many early forms are still widely used
(34). Materials used for industrial applications provided the earliest forms of
biomaterials because they were easily accessible. The only contingency governing their
use was that they be inert so as to limit immune responses or foreign body reactions in
the host (34). Biomaterials introduced in the 1940s included metal and metal alloy-based
implants (stainless steel, cobalt-chrome alloys, titanium, and titanium alloys); porous
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ceramics of alumina, zirconia, calcium; and polymers consisting of silicone rubber,
acrylic resins, polyurethanes, polypropylene, and polymethylmethacrylate (34). Second
generation biomaterials appeared between 1980 and 2000 and sought to enhance the
biological response from the host environment as a means of facilitating tissue/surface
bonding and bioabsorption (34). Bioactive materials that are still used clinically in fields
like dentistry and orthopedic surgery included bioactive glasses, ceramics (calcium
phosphate, β-tricalcium phosphate, and hydroxyapatite); bioactive ceramic-coated metals
(calcium phosphate and hydroxyapatite-coated titanium and titanium alloys); and
biodegradable polymers (polyglycolide, polyactide, polydioxanone, chitosan, hyaluronic
acid, hydrogels) (34, 35). Hydroxyapatite-coated titanium implants, in particular, have
been shown to help convert fibrous tissue to bone (36) and facilitate osteointegration
(37). However, bioabsorbable implants have several advantages over traditional metallic
implants including reduced stress shielding, elimination of surgeries to remove metallic
components, and a reduction in hypersensitivity and osteolytic responses in the recipient
(34). Indeed, hypersensitivity to metals and wear debris-induced osteolysis are still
prevalent concerns (38-40). Approximately one million total joint replacements are
completed world-wide each year (39). Many of the hip and knee prostheses are
comprised of a polymer-based cup (e.g., ultra-high molecular weight polyethylene
[UHMWP]) that articulates against a hard metal surface (39). Particulate debris from
these implants is generated by either wear or corrosion and accumulates in the
periprosthetic membrane and surrounding tissue where it is phagocytosed by
macrophages (40). The macrophages release pro-inflammatory cytokines such as tumor
necrosis factor-α (TNF-α) to recruit additional cells to the site in an attempt to evacuate
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the particles (39, 40). Macrophage-secreted TNF-α is thought to initiate osteolysis by
activating osteoclasts and bone resorption around the implant (39).
The most current conceptual transition of biomaterials has been to create implants
that stimulate the host environment to facilitate healing and tissue regeneration. In fact,
many commercially available products only provide for osteoconduction and
osteointegration but exhibit no other properties of natural bone (27, 41). These materials
are typically three-dimensional porous structures and can contain stem cells, growth
factors, and/or peptide sequences as a means of promoting cell invasion, attachment,
proliferation, and activation (34). Biomaterials have been combined with recombinant
growth factors (42, 43), biomolecules (44, 45), and stem cells (46, 47) in an effort to
achieve other natural bone properties. The repair and remodeling processes that will
incorporate and potentially replace the grafted material are dependent on the specific
interplay between local host cells and bioactive proteins at the surgical site.

Calcium-based Ceramics as a Synthetic Bone Graft Materials
Interest in implantable ceramic materials, including calcium aluminate and
calcium phosphates stems from early research in the 1970s (48, 49). The three main
calcium-based ceramics to be discussed are calcium hydroxyapatite (Ca10[PO4]6[OH]2),
tricalcium phosphate (Ca3[PO4]2), and calcium aluminate (CaO·Al2O3).
Calcium hydroxyapatite is derived from coral exoskeleton that is treated by a
hydrothermal exchange method to covert coral carbonate into pure hydroxyapatite (33).
The process removes residual organic matter and leaves behind a unique macroscopic
architecture similar to human cancellous (spongy) bone with pore sizes ranging from 500
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– 600 µm (33). Hydroxyapatite implants have been utilized in several animal models of
long bone, spinal, and mandibular defects where they generate a strong bone union with
no fibrous tissue (33). Upon implantation in the canine tibia, porous hydroxyapatite
demonstrates 50 percent greater strength than identical sites treated with cancellous bone
grafts for six months; however, in its unimplanted state, it is significantly weaker than
cancellous bone (33). The Food and Drug Administration (FDA) approved the use of
porous hydroxyapatite in humans for the repair of metaphyseal and diaphyseal defects in
long bones in 1982 (33).
Calcium phosphates, including tricalcium phosphate (TCP), have been
extensively investigated for use in dental and orthopedic settings. The synthesis process
begins with homogenization of the tricalcium phosphate powder with naphthalene.
During compaction of the mixture, the naphthalene is removed by sublimation, leaving
pores in the ceramic. The final step is a sintering process (>600oC) that fixes the pore
configuration and results in pore diameters ranging from 100 – 300 µm (33).
Fluctuations in sintering temperatures can greatly affect microporosity and crystal size
(35). Like hydroxyapatite, TCP has been tested in a variety of animal models which
support its low toxicity, rapid bone ingrowth, and biodegradation into natural calcium and
phosphate ions (33). The biodegradability of calcium phosphates is thought to occur, at
least in part, by cellular engulfment of the graft material or dissolution in acidic
microenvironments (35). However, the rate of biodegradation can be influenced by the
implant environment and the stability of the surrounding bone (33). Tricalcium
phosphates like β-TCP [Vitoss®, Cerasorb®] are used routinely for dental applications
such as the repair of periodontal defects, augmentation of alveolar bone, sinus lifts, and
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tooth replacement (35). In cases of defects in long bones or those created following
curettage of bone malignancy, TCPs have demonstrated adequate regeneration of new
bone and sufficient integration (31, 33). The use of TCP for spinal fusion has been tested
in several models. TCP produced better results than hydroxyapatite or calcium carbonate
in canines, improved fusion results over autologous bone in sheep, and was completely
integrated into the vertebrae of baboons (31). Despite the advantages of calcium
phosphate materials for bone regeneration, there is concern with the overall mechanical
integrity of these ceramics. Calcium phosphate ceramics are brittle, lacking substantial
mechanical strength, and require that the surrounding bone must be intact or rigidly
stabilized to shield the implant from loading during integration (31, 33). The implants
will fragment when subjected to shear forces (33). Although, β-TCP scaffolds implanted
in 8 mm calvarial defects in rats showed signs of osteointegration and neovascularization
after four weeks (50), substantial degradation prior to adequate bone fill may compromise
the integrity of the biomaterial and the defect site.
The unique combination of alumina and calcium as a ceramic implant for dental
applications was considered in the early 1970s. Acute toxicity testing revealed that
calcium aluminate (CA) lacked cytotoxic effects (48). Subacute toxicity testing
demonstrated that CA implanted in muscle pockets was well-tolerated and saline extracts
of calcium aluminate injected intradermally were non-irritating (48). Later testing of CA
in tibial and calvarial models was conducted by Uchida et al. Their studies revealed that
although porous CA implants were well-tolerated, tissue ingrowth into implant pores was
predominately acellular (i.e., fibers and extracellular matrix) even with larger pore sizes,
longer periods of implantation, and the presence of bone marrow (49, 51). Interestingly,
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signs of modest biodegradation of the CA implants were observed in calvarial defects
(49). While early studies support the biocompatibility of CA, more robust bone ingrowth
and integration are desired. Indeed, ceramic materials by nature are only osteoconductive
(35, 37). Thus, alternative calcium-based implants with adequate mechanical properties
to endure impact or weight-bearing forces while regenerating bone need to be considered
for these locations in conjunction with stimulatory factors that will facilitate their
integration.
Calcium aluminates are formed by the thermal treatment of an Al2O3 source and a
CaO source. The chemical composition of calcium aluminates results from the ratio of
Al2O3 to CaO and can produce a wide variety of chemical species. What is unique about
this process is that calcium aluminates are prepared by mixing the reactants with a small
amount of water resulting in a material that is moldable at room temperature for an
extended period of time. Moreover, traditional heat treatments (>600oC) used in the
synthesis and strengthening of other ceramics (35) are not required for the manufacture of
calcium aluminate scaffolds. Thus, there is a novel opportunity to functionalize CA
surfaces with a variety of biological agents. These advantages were exploited to enhance
the osteoinductive potential of CA scaffolds in the current study. To this end, two
therapeutic agents were utilized for their reported effects on bone formation, melatonin
and platelet-rich plasma.

Effects of Melatonin on Bone & Melatonin as an Osteoinductive Agent
Melatonin is a hormone synthesized and secreted into the systemic circulation
from the pineal gland during periods of darkness (52). The biochemical conversion of
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tryptophan to melatonin in pinealocytes has been well-described and is inhibited by light
(52). Its endogenous release is controlled by specific master clock cells located in the
suprachiasmatic nucleus (SCN) and it has been implicated in circadian entrainment of
peripheral clocks (53, 54). Melatonin affects several physiological systems including
those involved in sleep, immune defense, detoxification, reproduction, and bone
maintenance either by receptor-dependent or receptor-independent actions (54). The
endogenous levels of melatonin decline with age, the onset of menopause, inactivity or
immobility, and exposure to artificial light at night (10, 54, 55).
Melatonin deficits have been theorized to be implicated in the etiology of bone
diseases like osteoporosis and adolescent idiopathic scoliosis (56, 57). With age, bone
marrow cell differentiation shifts towards an adipocyte lineage, reducing the formation of
osteoblasts, increasing fat cell accumulation in the marrow, and contributing to
osteoporosis risk (58). These alterations coincide with the decline in melatonin levels
with age, implying that melatonin production and bone homeostasis are closely linked.
Artificial light at night can suppress melatonin production and function. In a study of
female nightshift workers exposed to light at night, women working nightshift had an
increased risk of hip and wrist fractures over eight years of follow-up compared to
cohorts that never worked nightshifts (10). Animal studies support these findings, as
exposure to longer periods of light disrupted bone turnover in rats (59). Moreover, longday conditions decreased the average circadian melatonin concentration and abolished the
rhythmicity of the circadian peak (59). A separate study by the same authors found that
pinealectomy induced biochemical markers of bone metabolism, while exogenous
melatonin administration suppressed the same markers (60). These studies suggest that
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lighting conditions can affect that normal pattern of melatonin production and secretion,
and that melatonin production and secretion are an important mechanism regulating bone
turnover activity in both animals and humans.
Persistent osteopenia, a condition where bone mineral density is lower than
normal, is a hallmark of adolescent idiopathic scoliosis (AIS). Several human and animal
studies have investigated the role melatonin may play in the etiology of AIS given its
reputed effects on bone. The main hypothesis that melatonin deficiency is linked to AIS
stems from studies in which pinealectomy of chickens and rats results in scoliosis that
resembles the AIS pathology (57). Similar effects in fish suggest that gravity may not
affect the response to pinealectomy with regard to the development of scoliosis (61).
Surgically induced bipedalism in pinealectomized mice also results in scoliosis (62);
however, the same is not true for non-human primates (57). Therefore, whether or not
the results of experiments in lower animals can be extrapolated to humans remains to be
determined. Nonetheless, genetic studies of AIS patients reveal that polymorphisms of
the MT2 receptor gene could predispose an individual to AIS (57), and that promoter
polymorphisms of the MT1 receptor gene are likely not involved (63). Moreau and
colleagues believe that the response to melatonin (i.e., inhibition of forskolin-induced
cAMP accumulation in primary osteoblasts), not melatonin synthesis or the expression of
melatonin receptors, could underlie AIS is humans (64). Indeed, their research has
demonstrated an impaired melatonin signaling response in osteoblasts isolated from AIS
patients (64) that could be the result of phosphorylation of serine residues affecting the
activity of G inhibitory (Gi) proteins normally associated with melatonin receptors (65).
Work by other authors suggests that the dysfunction in melatonin signaling in the
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osteoblasts of AIS patients in due to abnormal MT 2 melatonin receptor expression (66).
Work completed by Radio et al. (2006) and Sethi et al. (2010) support the notion that the
MT2 melatonin receptor may be important for regulating the activity of osteoblast (67,
68). These studies further support the connection between melatonin and bone
physiology.
To date, there is only one clinical trial focused on the use of melatonin as a
therapeutic intervention for the preservation of bone (Identifier# NCT01152580) (69), yet
several studies have demonstrated that melatonin prevents bone deterioration in fish (61),
chickens (70, 71), and mice (62). Melatonin is hypothesized to have three principle
actions on bone metabolism including (1) the promotion of osteoblast differentiation and
activity (52, 57, 67, 68, 72), (2) the suppression of osteoclast activity via its increase in
osteoprotegrin and actions on receptor activator of NF-κB ligand (RANKL) (57, 73), and
(3) potential scavenging of free-radicals generated by osteoclast-mediated bone
resorption (57) (Fig. 4).
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Figure 4. Proposed Mechanism of Melatonin on Bone Homeostasis
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Figure. 4. Melatonin acts through many levels to modulate bone homeostasis. (1) Melatonin
induces osteoblast differentiation through MT2 receptors located on hAMSCs. (2) Melatonin
induces the expression of osteoprotegrin (OPG) in osteoblasts, which acts as a decoy receptor
for receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL). Complexes formed
between OPG and RANKL prevent RANKL from binding to its receptor (RANK) on osteoclasts,
thus diminishing the formation and activity of new osteoclasts. (3) As a free-radical scavenger,
melatonin may prevent radical-induced destruction of osteoblasts and osteoclasts to prevent
bone loss. Copyright 2011. From Melatonin in the Promotion of Health by Ronald Ross Watson
(ed.). Reproduced by permission of Taylor and Francis Group, LLC, a division of Informa plc.

In pre-osteoblast cultures from rats and fully differentiated osteoblast-like cell
lines, melatonin augments expression of the bone formation markers bone sialoprotein
(BSP), alkaline phosphatase (ALP), osteopontin, and osteocalcin in a dose-dependent
manner (72, 74). Also, melatonin promotes the proliferation of human bone cells and
their synthesis of collagen type I, a major determinant of bone strength (75). Bone
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marrow cells from both mice and humans contain high concentrations of melatonin and
express the mRNA encoding the rate-limiting synthesis enzyme for melatonin
production, N-acetyltransferase (76). Thus, the local production and secretion of
melatonin in bone and its varied effects on bone remodeling may underlie its regulation
of bone physiology. In fact, the modulatory effects of melatonin on both the anabolic and
catabolic processes of bone remodeling has highlighted its potential use as an adjuvant
therapy in osteoporotic populations (14, 54).
Likewise, several studies have supported the use of topically applied melatonin to
facilitate the integration of bone implants. The topical application of 1.2 mg of
lyophilized melatonin powder facilitated the osteointegration of titanium dental implants
in Beagle dogs over a 2 – 8 week period (74, 77). Secondary four-week studies of
platform implants in the mandibles of Beagle dogs demonstrated that 5 mg of lyophilized
melatonin powder combined with collagenized porcine bone increased bone perimeter
contact, bone density, and new bone formation in defects over collagenized porcine bone
alone (78, 79). Moreover, melatonin accelerated the regeneration of cortical bone in
tibial defects in rabbits when delivered as a 5 mg dose in resorbable Alveoprotect (a
collagen fleece made from porcine dermis) (80). These studies substantiate claims that
melatonin may have osteoinductive effects, both alone and when combine with
supportive biomaterials, which accelerate the synthesis and mineralization of new bone.

Effects of Platelet-Rich Plasma on Soft and Hard Tissue Healing
Much of the biological stimuli for soft and hard tissue repair as well as
angiogenesis originate from platelets activated at the site of injury (81). Platelets have
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critical rolls in both soft and hard tissue healing including hemostasis, controlling
inflammation, and the initiation of several growth factor-mediated signaling cascades
(82). Platelets normally circulate in the blood as an inactivated, spheroid. Platelets are
subsequently activated in response to tissue damage or vascular exposure (83). When
activated, platelets undergo a process of degranulation in which several cytokines and
growth factors are released into the surrounding environment from cytoplasmic αgranules (Fig. 5). The approximately 50 – 80 α-granules they contain hold over 30
bioactive proteins (82). The growth factors and cytokines released contribute to cell
recruitment, proliferation, differentiation, and matrix synthesis (82).
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Figure 5. Activation of Platelets and Platelet Degranulation
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Figure 5. Platelets circulate as inactive spheroids. Activators such as von Willebrand factor,
collagen, adenosine diphosphate (ADP), serotonin, or thromboxane induce a change in platelet
morphology. Morphological changes in platelets promote the degranulation of α-granules,
whereby growth factors, cytokines, clotting factors, and adhesion proteins are released into the
microenvironment. Figure created by William P. Clafshenkel.

Platelet-rich plasma (PRP) has a 4 to 5-fold increase in platelet numbers above
baseline, is a proven source of growth factors, and can be readily prepared from whole
blood (81, 84, 85). Most individuals have a baseline blood platelet count of 200,000 ±
75,000/µL; therefore, a PRP platelet count of 1 million/µL has become the benchmark for
“therapeutic PRP” (81). After clot formation, 95% of the growth factors concentrated in
PRP are bioavailable after one hour (86). The seven main growth factors in PRP that
likely contribute to the healing and remodeling of bone are vascular endothelial cell
growth factor (VEGF), epidermal growth factor (EGF), platelet-derived growth factor
(PDGF) αα, PDGF ββ, PDGF αβ, transforming growth factor (TGF)β-1, and TGFβ-2
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(86). Many of these growth factors are significantly increased over baseline levels in
whole blood, which while not appreciably affected by donor age or gender, can vary
slightly with collection and activation methods (82, 87). PRP also contains three main
adhesion proteins implicated in osteoconduction and extracellular matrix formation
including fibrin, fibronectin, and vitronectin (81) as well as the full complement of
clotting factors (83). The activity of these specific growth factors and adhesion proteins
are summarized in Table 1 below. The infiltration of macrophages in response to PDGF
becomes the primary source of growth factors and neovascularization after the platelets
expire (81).
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Table 1. Major Growth Factors and Adhesion Proteins Found in PRP

Growth Factor

Function

Mean PRP
Concentration
 51 pmol/L

 Stimulates the proliferation of
chondrocytes
 Chemoattractant for fibroblasts and
 Epidermal
epithelial cells
Growth Factor
 Promotes angiogenesis
 Influences the synthesis and turn-over
of extracellular matrix
 α and β isoforms are potent mitogens
 αβ: 117.5 ng/mL
for fibroblasts, chondrocytes, and
epithelial cells
 ββ: 9.9 ng/mL
 Platelet-derived
 Potent chemoattractant for
Growth Factor
hematopoietic and mesenchymal cells
and fibroblasts
 Activates TGF-β
 Stimulates fibroblast chemotaxis and
 β1: 169.9 ng/mL
proliferation
 Stimulates synthesis of extracellular
 β2: 0.4 ng/mL
 Transforming
matrix
Growth Factor-β
 Decreases dermal scarring
 Antagonizes the biological activities of
EGF, PDGF, FGFα and FGFβ
 Stimulates the proliferation of
 76 – 854 pg/mL
 Vascular
endothelial cells
Endothelial
Growth Factor
 Induces neovascularization
 Fibrous protein formed by the
conversion of fibrinogen by thrombin
 Fibrin
 Functions in blood coagulation,
platelet activation, and protein
polymerization
 Extracellular matrix protein that binds
other proteins including integrins,
fibrin, collagen, and syndecans
 Fibronectin
 Secreted by fibroblasts during matrix
synthesis
 Functions in cell adhesion, migration,
and differentiation
 Abundant glycoprotein of the
extracellular matrix
 Vitronectin
 Promotes hemostasis and cell
migration, adhesion, and spreading
Table 1. Table adapted from Alsousou J. et al. 2009. J Bone Joint Surg [Br].

The use of PRP is wide-spread in the dental industry and in oral and maxillofacial
surgery. It is routinely used in conjunction with dental implant procedures as well as in
the treatment of diabetic ulcerations, slow healing wounds, soft tissue loss due to trauma,
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and plastic surgery (88-91). It is hypothesized that the effects of PRP on bone formation
and healing are due to its modulation of specific growth factors (81, 86, 92) or its effects
on local cells (82). Osteoblasts, fibroblasts, endothelial cells, and adult mesenchymal
stem cells have surface receptors for the growth factors found in PRP (86). In vitro, there
is a dose-response relationship between platelet concentration and the proliferation of
human adult mesenchymal stem cells and fibroblasts, and the production of type I
collagen (82).
The promotion of bone regeneration with PRP has been investigated in several
model systems both alone and in combination with other graft materials. The topical
application of prepared PRP to human molar extraction site accelerated healing time
(from 6 weeks in control sites to 2 weeks in PRP-treated sites) and augmented bone
regeneration over a 12-week period (93). The application of thrombin-activated PRP to
open femur fractures in Lewis rats increased bone formation and strength at 4 weeks
compared to saline-treated controls (92). Bone regeneration in 10 mm circular calvarial
defects was significantly enhanced in New Zealand rabbits after 4 weeks with the topical
application of PRP (94).
Other studies have examined the bone-regenerating capacity of PRP when
combined with autogenous bone, titanium implants, and commercially available bone
substitutes. The combination of PRP with autogenous bone in maxillary sinus grafts in
humans increased new bone formation over autogenous bone alone at three months (95).
PRP potentiated the formation of new bone in critical-sized calvarial defects in mini-pigs
when combined with autogenous bone; however, the effects of PRP were lost in the
autogenous bone group after four weeks as detected by microradiographic assessment of
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bone mineralization. Further, PRP did not appreciably affect bone regeneration when
combined with commercially available biomaterials (Cerasorb®, β-tricalcium phosphate;
Bio-Oss®, bovine sponginous bone block; or Colloss®, bovine collagen sponge) (96).
The authors speculated that the short-lived mitogenic effects of PRP were likely
responsible for the decrease in PRP response over time (96). Bone formation around
laminar titanium implants in Wistar rats benefited from the application of PRP compared
to untreated implants (97). PRP added to polycaprolactone-20% tricalcium phosphate
composites fitted with titanium implants accelerated bone regeneration and increased
bone volume at 6 and 9 months in mandibular defects of mongrel dogs (98).
Interestingly, when PRP was combined with mesenchymal stem cells on
fluorohydroxyapatite (FHA) scaffolds, bone formation in premolar extraction sites in
mini-pigs was greater than FHA-treated sites or sites treated with autogenous bone after
three months (99). Although a FHA-MSC group was not included as a means of
comparison, the authors attributed the results of the FHA-MSC-PRP group to the ability
of PRP to enhance MSC proliferation, thereby increasing the pool of progenitor cells
capable of differentiating into osteoblasts (99). These findings suggest that the effect of
PRP on mesenchymal stem cells, the host microenvironment, and its interaction with
specific biomaterials may be important for bone formation in certain models.

Mesenchymal Stem Cells as a Model System for Studying Bone Formation Potential
Remodeling processes in the adult human that regenerate and repair damaged
tissue require a constant supply of new cells, either local or circulating, that have retained
the capacity to proliferate and differentiate into terminal lineages of many types (5).
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Human bone marrow contains hematopoietic stem cells that provide eight distinct
lineages comprising the hematopoietic system as well as stromal stem cells (i.e.,
mesenchymal stem cells, MSCs) (5). Mesenchymal stem cells can also originate from
the periosteum and limited sources have been identified in muscle, fat, and synovium (4).
Mesenchymal stem cells are a pluripotent population that can give rise to fibroblasts,
osteoblasts, chondrocytes, tenocytes, myoblasts, and adipocytes (4). Mesenchymal stem
cell differentiation into osteoblastic, chondroblastic, or fibroblastic lineages is directed by
the local environment, including specific cytokines and cell-cell or cell-matrix
interactions (5, 6). Osteoprogenitor cells derived from MSCs, are responsible for the
expansion of osteoblast numbers via a transition through a pre-osteoblast stage whereby
they become mature osteoblasts (6) (Fig. 6).
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Figure 6. Transition of Mesenchymal Stem Cells into Mature Osteoblasts
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Figure 6. In the early stages of differentiation, mesenchymal stem cells proliferate into
osteoprogenitor cells and pre-osteoblasts. Proliferation slows in latter stages of differentiation as
pre-osteoblasts become mature osteoblasts. Following synthesis and mineralization of the bone
matrix, osteoblasts are subject to one of three fates: lining cells, osteocytes, or apoptosis. Figure
created by William P. Clafshenkel.

Mesenchymal stem cell number and activity is greatest in metaphyseal bone and
areas of thick and vascular periosteum (e.g., long bones like the femur), which
contributes to more robust healing at these locations (4). Although MSCs are still found
in the bone marrow of older individuals, their numbers do decline with age (5) and
osteoporosis (6), as does their potential for osteoblastic differentiation (100, 101). It is
theorized that this reduction in the ability of MSCs to replace needed osteoblasts in the
aged individual underlies the pathogenesis of osteoporosis (102).
Three criteria to identify MSCs have been proposed by the Mesenchymal and
Tissue Stem Cell Committee of the International Society for Cellular Therapy including
(1) the plastic adherence of isolated cells in culture, (2) the positive surface expression of
CD105, CD73, and CD90, (3) the lack of surface expression of CD34, CD45, CD14 or
CD11b, CD79a or CD19, and HLA-DR (100). MSCs can secrete a variety of angiogenic,
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anti-apoptotic, and mitogenic factors such as vascular endothelial cell growth factor
(VEGF), hepatocyte growth factor (HGF), angiopoietin-1, and insulin-like growth factor1 (IGF-1) (100). Mesenchymal stem cells can reproducibly be induced into an
osteoblastic lineage in vitro; however, this requires that they be exposed to optimal
concentrations of dexamethasone, ascorbic acid, and β-glycerophosphate (103).
Mesenchymal stem cells cultured under these conditions assume a cuboid morphology,
have enhanced alkaline phosphatase activity, express osteoblastic cell surface antigens,
modulate the synthesis of bone-forming genes, and produce mineralized nodules within
16 days (103). The average number of population doublings in cultured MSCs decreases
with continued passaging; however, their osteogenic potential is conserved (103).
Additionally, cryopreservation techniques do not affect the proliferation, differentiation,
or osteogenic activity of cultured MSCs (103). It has been suggested that “young” MSCs
(less than 10 passages) and more frequent media changes produce the best growth rates
(103). Mesenchymal stem cells respond robustly to melatonin. Melatonin, via MT 2
melatonin receptors, increases the differentiation of MSCs into osteoblasts as shown by
an increase in alkaline phosphatase activity and an increase in calcium deposition in
culture (68). Additional work indicates that melatonin may regulate MSC differentiation
and mineralization by inducing the expression of specific bone markers (68).

Statement of Problem & Study Objective
The treatment of bone loss, whether great or small, continues to be at the forefront
of scientific research. The practice of tissue engineering combines several disciplines in
an attempt to restore, rebuild, or replace pathological or traumatic bone loss. The costs
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associated with treating bone loss continue to rise as more of the population reaches an
elderly age. Complications with traditional methods of bone grafting or the utilization of
commercially available bone substitutes warrants further research on biomaterials
capable of replicating native bone tissue. To achieve this, unique biomaterials are being
developed for the guided delivery of agents that stimulate the normal bone repair and
restoration processes.
In this study, the biomaterial calcium aluminate (CA) was used to create synthetic
scaffolds with the potential to deliver biomolecules, like melatonin, to bone defect sites
through surface chemistry. Indeed, peptide attachment to the calcium aluminate surface
can be accomplished through simple linker chemistry (50). Additionally, calcium
aluminate meets many of the criteria for an ideal synthetic bone substitute including low
toxicity and high mechanical strength (48, 104). Two therapeutic strategies were
investigated in the current study, (1) the local delivery of melatonin by chemical
attachment to the surface of the calcium aluminate scaffold and (2) the topical application
of PRP at the bone defect site in conjunction with the developed scaffolds. Given the
extensive effects of melatonin and PRP on bone formation and the characteristics of
calcium aluminate as a synthetic bone substitute, it was hypothesized that the cooperative
interaction between melatonin, PRP, and calcium aluminate would be a novel therapy to
facilitate bone regeneration in a model of calvaria defects.

Hypothesis
Melatonin and/or platelet-rich plasma will provide osteoinductive properties to calcium
aluminate scaffolds to enhance local bone regeneration.
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Specific Aims
1. Assess the effects of unmodified (CA) and modified (CA-Melatonin) scaffolds on
human adult mesenchymal stem cell (hAMSC) differentiation and morphology in
the presence or absence of PRP.
2. Assess the effects of unmodified (CA) and modified (CA-Melatonin) scaffolds on
bone formation and remodeling activity in the presence or absence of PRP in a
rodent model of calvarial defects.

METHODS
1

Synthesis of Modified and Unmodified Calcium Aluminate Scaffolds

1.1

Casting Calcium Aluminate
Calcium aluminate disks were prepared as previously described (50) by a room

temperature cast of different sized CA aggregates. Fifty percent -325 and 25 percent each
of -30 + 60 and -60 sized aggregates were combined to form the CA scaffold. This
mixture was chosen because of its durability and optimal pore size. The number -30 +60
means that the cement was passed through the mesh screen with 30 squares per inch and
caught on the mesh screen with 60 squares per inch. If there is no + mesh number
indicated, the cement was caught on a flat board. The larger the mesh numbers, the
smaller the aggregate size (e.g., -325 is a fine powder-like cement). CA is a hydratable
material that can be molded and shaped at room temperature for extended periods of time
before setting. The CA aggregates were first dry mixed to ensure equal particle
distribution. After dry mixing, double-distilled water was added to achieve a cement
paste that was allowed to thicken over 20 minutes at room temperature. Upon thickening,
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the cement was poured into a mold and allowed to set overnight at room temperature.
Unmodified scaffolds were then sterilized by autoclaving at 121 oC and 18 psi of steam
for 60 minutes with fast exhaust (standard sterilization procedures for dry materials).
Modified scaffolds were prepared with melatonin as described (Section 1.2). Seven
millimeter diameter disks were used for in vitro assays. Six by six by one millimeter
square scaffolds were implanted in vivo. The creation of unmodified and modified
scaffolds for analyses was carried out in Dr. Gawalt’s laboratory by Rachelle Palchesko
and Jared Romeo.

1.2

Chemical Linkage of Melatonin to the CA Surface
Melatonin was attached to the CA surface (modified scaffold; CA-Mel) via a

chemical linker through a two-step solution deposition process (105). This method
provided for a prolonged attachment of melatonin to the CA surface versus other weak
attachment methods like adsorption. First, the scaffolds were placed in a 2 mM 12bromododecanoic acid in dry tetrahydrofuran (THF) solution for one hour at room
temperature. The scaffolds were removed and placed in a 120oC oven for 24 hours. The
scaffolds were then immersed in a 1 mg/mL solution of melatonin in methanol with 1%
pyridine at 4oC for 24 hours and dried under vacuum for an additional 24 hours. A
Thermo Nicolet Nexus 470 FT-IR Spectrophotometer equipped with diffuse reflectance
was used to obtain the IR spectra of the substrates after each deposition step to confirm
the attachment of melatonin to the CA surface. Modified scaffolds were then sterilized
by autoclaving at 121oC and 18 psi of steam for 60 minutes with fast exhaust. Separate
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diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy analysis was used to
confirm the attachment of melatonin after sterilization.

2

Cell Culturing & Cell-based Assessments
Culturing experiments for viability assessments (Section 2.1) were set up as

follows: NIH 3T3 fibroblasts (from Swiss albino mice, Cat# CCL-92; ATCC, Manassas,
VA) were cultured on unmodified or modified scaffolds at an initial seeding density of
10,000 cells/mL in DMEM plus 10% FBS in 48-well plates. Normal human osteoblasts
(Nhost; Cat# CC-2538; Lonza, Walkersville, MD) were cultured on unmodified or
modified scaffolds at an initial seeding density of 10,000 cells/mL in OGM medium in
48-well plates. Cells were incubated under 90% humidity at 37oC and 5% CO2.
For differentiation and morphology experiments (Section 2.2 and 2.3),
multipotent human adult mesenchymal stem cells (hAMSCs; Cat# PT-2501; Lonza,
Walkersville, MD) were cultured on unmodified or modified scaffolds at an initial
seeding density of 20,000 hAMSCs/mL in chemically-defined basal medium (OS-;
Lonza, Walkersville, MD) in 48-well plates. Human adult mesenchymal stem cells
utilized in this study were collected from human bone marrow withdrawn from the
posterior iliac crest of normal volunteers (106). The hAMSCs have been flow sorted by
testing for the following antigens: CD105+, CD166+, CD29+, CD44+, CD14-, CD34-,
and CD45- (106). Cells between 3-4 passages were used. After 24 hours, waste media
was removed and the seeded scaffolds were transferred to individual wells of a sterile 24well plate. Fresh osteogenic medium (OS+) was then added to each well. Waste media
was replaced every 3 days up to 7 or 14 days. These time points have been shown to be
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specific to heightened hAMSCs differentiation and alkaline phosphatase activity and
occur before significant mineralization (67, 68, 103). Osteogenic medium was prepared
by supplementing chemically-defined basal medium with 0.1 µM dexamethasone, 10
mM β-glycerophosphate, and 0.3 mM ascorbic acid. This medium is required to induce
hAMSC differentiation towards an osteoblast phenotype (67, 68, 103). Ascorbic acid
acts as a cofactor in the hydroxylation of proline and lysine residues for collagen
formation and increases the synthesis of non-collagenous bone matrix proteins (107).
The glycerophosphate is rapidly degraded to inorganic phosphate by alkaline phosphatase
enzyme activity, whereby the inorganic phosphate is free to combine with calcium to
form mineralized nodules (107). Glucocorticoids like dexamethasone are essential for
the induction of osteoblast differentiation and production of a mineralized matrix (108).
Dexamethasone reliably stimulates the development of many of the phenotypic features
of human osteoblasts (109). Differentiation and matrix formation are regulated by the
binding of dexamethasone to the glucocorticoid receptor-α (GRα), which in turn,
modulates gene expression of osteocalcin, collagenIα1, and transforming growth factorβ1 via GC responsive elements (108). Cells were incubated under 90% humidity at 37oC
and 5% CO2.

2.1

Live/Dead Assay
After 1, 4, and 7 days, the viability of the NIH 3T3 and Nhost cells on unmodified

and modified scaffolds was determined using a Live/Dead® Viability/Cytotoxicity Assay
Kit (Molecular Probes, Invitrogen, Carlsbad, CA). After removing waste media and
washing twice with 1x PBS, cells were stained with a 2 µM calcein AM and 4 µM
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ethidium homodimer (EthD-1) at 37oC for 30 minutes. Live cells are distinguished by
the enzymatic conversion of the nonfluorescent cell-permeant calcein AM to intensely
fluorescent calcein by ubiquitous intracellular esterase activity. Calcein has an excitation
wavelength of 485 ± 10 nm and produces green fluorescence in live cells. Dead cells
with damaged membranes allow the passage of EthD-1 into the nuclear compartment
where it binds to nucleic acids. Binding to nucleic acids enhances EthD-1 fluorescence
40-fold. EthD-1 has an excitation wavelength of 530 ± 12.5 nm and produces red
fluorescence in dead cells. Background fluorescence with this technique is minimal
because both probes are virtually nonfluorescent before interacting with cells. Samples
were viewed using a Zeiss Axioskop 2 under 10x magnification and five images per
sample with an area of 0.6 mm2 were taken using a Zeiss Axiocam. The number of live
and dead cells per view was counted using Axiovision 4 software. The assessment of
NIH3T3 fibroblast and normal human osteoblast adhesion and viability on calcium
aluminate surfaces was carried out in Dr. Gawalt’s laboratory by Rachelle Palchesko and
Jared Romeo.

2.2

Preparation and Application of Platelet-Rich Plasma for In Vitro Studies
Platelet-rich plasma utilized for in vitro experiments was obtained from a human

female subject with approval from the Duquesne University Institutional Review Board.
Approximately 4 mL of blood was collected in a 4.5 mL BD Vacutainer™ tube
containing 0.45 mL of the anticoagulant trisodium citrate (9:1) to prevent clotting (BD,
Franklin Lakes, NJ). The whole blood was centrifuged and the PRP layer was collected
as described in Section 3.3. The hAMSCs were plated and cultured as described in
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Section 2 with the following modifications. Unmodified and modified CA scaffolds were
seeded with hAMSCs in basal medium in 24-well plates. Twenty-four hours after initial
seeding, waste medium was removed and hAMSCs were exposed to basal medium
containing PRP. The harvested PRP (approximately 375 µL) was thoroughly mixed with
15 – 20 mL of warm, sterile basal medium before dispensing approximately 1 mL into
each well. After 24 hours, waste media and clotted PRP were removed. The seeded
scaffolds were washed twice with sterile 1x DPBS and then covered with osteogenic
medium. Waste media was replaced every 3 days up to 7 or 14 days. As described in
later sections, given the difficulties associated with these experiments and based on the in
vivo results of PRP-treated groups, this arm of the in vitro aim was no longer pursued.
Nonetheless, modifications to the experimental protocol will be addressed in future
studies.

2.3

Alkaline Phosphatase Assay
Alkaline phosphatase activity was qualitatively assessed as a marker of osteoblast

differentiation and activity (Alkaline Phosphatase Kit, Cat# 85L3R, Sigma-Aldrich, Inc.,
St Louis, MO). Human adult mesenchymal stem cells were cultured as described for 7 or
14 days. At each end point, scaffolds were washed twice with 1x PBS, then fixed for one
minute with a 20% citrate/80% methanol solution. Scaffolds were washed twice with 1x
PBS after fixing. Staining was completed with a diazonium salt/naphthol AS-MX
phosphate alkaline solution. As a result of alkaline phosphatase activity, the substrate
naphthol AS-MX phosphate is hydrolyzed to naphthol AS-MX, which immediately
couples with the diazonium salt forming an insoluble, visible red pigment at sites of
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phosphatase activity. A greater intensity of red staining indicates greater ALP activity.
After 30-45 minutes of incubation at 37oC, digital images were captured on a Nikon
Steroscopic Zoom dissecting microscope equipped with an Olympus DP70 microscope
digital camera. Scale bars were inserted digitally using NIH Image J.

2.4

Qualitative Alizarin Red S Staining
Calcium deposition occurs as bone matrix secreted from osteoblasts becomes

mineralized and is a definitive sign of osteoblast differentiation and activity (1). In
culture, mineralization by differentiated hAMSCs takes place between 14 and 21 days
(68). Alizarin Red S, an anthraquinone derivative, chelates calcium ions in biological
tissues and was used as a qualitative indicator of calcium deposition by hAMSCs on
unmodified and modified CA surfaces. The hAMSCs were cultured as described above
for 21 days in osteogenic media. For analysis, waste media was removed and scaffolds
were fixed with 10% buffered formalin for 30 minutes at room temperature. The fixative
was removed and replaced by 2% Alizarin Red S solution (pH 4.2; Sigma-Aldrich, Inc.,
St Louis, MO). After 10 minutes of incubation at room temperature, the stain was
removed and the scaffolds were washed twice with nanopure water. Digital images were
captured on a Nikon Steroscopic Zoom dissecting microscope equipped with an Olympus
DP70 microscope digital camera. It should be noted that the nonspecific binding of
Alizarin Red S to calcium made it difficult to distinguish calcium that had been deposited
as a result of hAMSC mineralization activity from the calcium component of the CA
scaffolds. In the future, fluorescent probes that specifically bind to the hydroxyapatite
component of mineralized nodules, rather than calcium ions, will be used to circumvent
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this issue. For the current study, ALP assays were used as an indication of mature
osteoblasts activity.

2.5

Scanning Electron Microscopy
For scanning electron microscopy, hAMSCs were cultured as described. At the 7

and 14 day end points, scaffold were processed by a modified protocol (110). Briefly,
media was removed and the seeded scaffolds were fixed in 2 % formaldehyde in 0.2 M
phosphate buffer (pH 7.4) for 5 days at 4oC. Individual scaffolds were then removed
from the fixative, washed twice with 1x PBS, and immersed in 0.5 mL of 2 % osmium
tetroxide (OsO4; Sigma-Aldrich, Inc., St Louis, MO) for 1 hour at room temperature with
gentle rocking. After 1 hour, the OsO4 was removed and samples were washed 3 times
with 1x PBS before being dehydrated through a graded ethanol series (in order: 25%,
50%, 70%, 95%, 100%). Following dehydration, scaffolds were transferred to
hexamethyldisalizane (Sigma-Aldrich, Inc., St Louis, MO) for 10 minutes. Scaffolds
were placed in clean glass scintillation vials and stored in a dessicator until imaging.
Imaging was completed on a Hitachi S-3400N-II Variable Pressure scanning electron
microscope under vacuum using Hitachi S-3400N software. Scale bars were inserted
digitally using NIH Image J.
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3

Calvarial Defect Model & Implantation

3.1

Pre-Surgical Preparation
Thirty three two-month-old ovariectomized female Sprague-Dawley rats (250-300

g; Hilltop Lab Animals Inc., Scottsdale, PA) were randomized and implanted with one of
four scaffold types: calcium aluminate alone (CA; unmodified) or CA with chemically
attached melatonin (modified; CA-Mel) in the absence or presence (CA + PRP, CA-Mel
+ PRP) of PRP. Animals were ovariectomized prior to transport to the Duquesne
University Animal Facility and approximately 3 weeks prior to surgery to ensure estrogen
levels had time to subside and create an imbalance in bone remodeling activity similar to
a post-menopausal population (111). Estrogen has inherent effects on the bone
remodeling process (112) and was thus considered a confounding variable for bone
regeneration in this model. An ovariectomized model system is commonly used in
research studies when mimicking post-menopausal bone loss is desired. Cancellous bone
in the proximal tibia is progressively lost, being evident at two weeks and unequivocal at
one month following ovariectomy (111). All surgical procedures were in accordance
with Duquesne University IACUC Guidelines. Animals were anesthetized with sodium
pentobarbital (10 mg/kg, IP; Nembutal®/Pentobarbital Sodium Injection USP, Butler
Schein Animal Health, Dublin, OH) twenty minutes prior to the procedure and given 3%
isoflurane by nosepiece to maintain anesthesia if necessary. The incision site was
shaved and disinfected with iodopovidone solution. A full-thickness flap was initiated
with a 1.2 cm incision through the skin and subcutaneous fascia at the most superior
aspect of the frontal bone 3 to 4 mm posterior to the junction of the nasal and frontal bone
and running posterior to the parietal bone. The periosteum was reflected bilaterally with
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blunt dissection to expose the cranial bone.

Calvarial defects were created in the

exposed cranial bone as described below (Section 3.2).

3.2

Piezotome Surgical Protocol for Calvaria Osteotomy
Rodent models of critical-size calvarial bone defects have been widely used to

study approaches designed to regenerate bone (13). In the current study, critical-size
defects (6-mm x 6-mm) were created in the calvarial bone of ovariectomized SpragueDawley rats. This defect size will not heal spontaneously over the lifetime of the animal
(13, 113). As larger rodents compared to mice, rats were chosen to improve the technical
ease of generating cranial bone defects. Given the relatively sparse bone remodeling that
occurs in calvarial bone (114), this site provides a suitable challenge to investigating the
osteoconductive and osteoinductive nature of the designed therapies. While the defect
size chosen was small enough to create two defects per animal, laterally performed
craniotomies may impair local regeneration due to the close vicinity of adjacent defects
(13). Thus, only a single defect was created in the skull of each animal.
Using a #4 round diamond bur in a slow speed electric handpiece, a 6-mm x 6mm outline was made in the superior aspect of the frontal bone under constant irrigation
with saline. Once the outline was thinned with the diamond bur, the final cuts were made
with an ultrasonic Piezotome™ handpiece. The Piezotome™ allowed for cutting of the
calvarial bone without affecting the underlying cerebral hemispheres or meninges. This
methodology significantly reduced the risk of defect site morbidity and animal mortality
in experimental groups while allowing for an easily reproducible defect. Likewise, in
comparison studies with other available ultrasonic devices, the PiezotomeTM has
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demonstrated significantly better cutting performance and produced the smallest increase
in operating temperature at the osseous surface (115). Care was taken not to damage the
middle cerebral artery, superior cerebral veins, inferior cerebellar vein, and the superior
sagittal sinus. Upon removal of the bone, an unmodified or modified calcium aluminate
scaffold was placed into the osteotomy site. For groups receiving PRP, the scaffold was
first covered with a few drops of the collected PRP in a sterile dish and the remainder of
the PRP was added to the superior surface of the bone defect after placement of the
implant. Incision closure was achieved with 3 surgical stables, as the dura and overlaying
skin provide adequate support for implanted materials without the need for internal or
external fixation (13).
Figure 7. Creation of Calvarial Bone Defects in Cadaver Rat Skull with Piezotome
A

B

C

Figure 7. Creation of calvarial defects in cadaver rat skull using Piezotome. (A) The calvarial
bone defect in skull is outlined using the Piezotome handpiece. (B) Double calvarial bone defect
in cadaver rat skull with defect bone removed. Notice the meninges and soft tissue are intact and
without damage. (C) Pieces of calvarial bone removed from the created defects. In the current
study, only one defect was made in the calvarial bone per animal.

3.3

Preparation and Application of Platelet-Rich Plasma for In Vivo Studies
There are several commercially available products that mimic PRP and several

different preparation techniques (116); however, this study utilized autologous PRP that
was prepared with a relatively simple method to reduce platelet aggregation and optimize
growth factor concentrations (85). Moreover, this preparation technique has been used
previously to decrease the incidence of alveolar osteitis and enhance bone formation in
44

tooth extraction sites (93, 117). Platelet-rich plasma was prepared using blood collected
from age-matched ovariectomized female Sprague-Dawley rats. Donor rats were deeply
anesthetized with sodium pentobarbital (100 mg/kg, IP; Nembutal®/Pentobarbital
Sodium Injection USP, Butler Schein Animal Health, Dublin, OH) until all withdrawal
reflexes were absent. A 3 – 5 cm incision was made through the ventral body wall into
the abdominal cavity starting from just below the diaphragm. After retraction of the skin
layers and exposure of the abdominal aorta, a 21-gauge 1.5 inch latex-free needle affixed
to a needle adapter was inserted in the direction of the heart. Approximately 4 mL of
blood was collected in a 4.5 mL BD Vacutainer™ tube containing 0.45 mL of the
anticoagulant trisodium citrate (9:1) to prevent clotting (BD, Franklin Lakes, NJ).
Anticoagulant collection is necessary to prevent platelet degranulation and the release of
vital growth factors. Trisodium citrate is used to bind free calcium ions in the blood to
prevent coagulation (82). Micromolar concentrations of calcium and other activators
including von Willebrand factor, collagen, and substances released from the platelets
acting in autocrine or paracrine feedback loops will activate the PRP in the defect
environment after application (118). The tubes were spun for 10 minutes in a room
temperature table top centrifuge set at 1350 x g. Centrifugation times were based on
previous studies which show a greater than 6-fold increase in platelet concentration after
10 minutes of centrifugation (85). The centrifugation speed of 1350 g is sufficient to
create a buffy coat containing leukocytes, thus producing a leukocyte-rich preparation
(85). The leukocytes concentrated by this method are vital to reductions in infection. For
example, when PRP prepared by this method (i.e., containing the buffy coat) was applied
to soft tissue wounds of 14 patients, it lead to a fewer number infections and shortened
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their hospital stay (90). After centrifugation, the tubes were removed and allowed to set
upright for 3minutes. Platelet-poor plasma was removed down to the top of the PRP
level using a sterile syringe with a 21-gauge 1.5 inch latex-free needle. A separate,
identically prepared syringe was used to aspirate approximately 375 µL of PRP.

The

prepared PRP was immediately applied to the surgical site and implant, as this is the most
beneficial for growth factor concentration and platelet morphology (85).

3.4

Post-Surgical Follow-up
Antibiotic ointment was applied along the incision line immediately following

surgery. Post-surgical recovery included a subcutaneous 3 mL saline bolus for fluid
resuscitation and supplemental oxygen until the rats were responsive and able to exhibit
righting reflex. Rats were housed individually in soft-bedded plastic cages with free
access to food and water. Rats received a subcutaneous injection of Ketoprofen (10
mg/kg, SC; Butler Schein Animal Health, Dublin, OH) for analgesia, which was repeated
as necessary every 12 hours for pain management. Follow-up inspections of the surgical
site and records of body weight were continued on a regular basis until necropsy.

3.5

Double-Fluorochrome Labeling
Differences in bone remodeling between groups was assessed using a double-

fluorochrome injection series. Bone remodeling is a process that involves organic matrix
synthesis and mineralization of the organic material via osteoblast activity. The labeling
technique utilized in this study is a relatively simple method which takes advantage of
fluorescent bone markers (tetracycline antibiotic and calcein solution) to label and
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demarcate the zone of osteoid tissue (unmineralized matrix) from mineralized bone.
Fluorochromes like tetracycline and calcein are deposited in areas of the skeleton where
new bone matrix is being synthesized and their deposition is consistent with the pattern of
calcium deposition (119). Further, it has been suggested that the specific binding of
fluorochromes to newly mineralized surfaces is due to the smaller size of the apatite
crystals formed during the early stages of mineralization, compared with older
mineralizing sites (13). Tetracycline antibiotic (Bio-Mycin 200/Oxytetracycline, Butler
Schein Animal Health, Dublin, OH) and calcein (Sigma-Aldrich, Inc., St Louis, MO)
solutions were prepared in sterile 0.9% saline. Tetracylcine (20 mg/kg, SC) was
administered 10 days prior to necropsy. Calcein (20 mg/kg, SC) was administered 7 days
after tetracycline and three days prior to necropsy. Animals were lightly sedated with 3%
isoflurane and the skin on the back of the neck was tented. Injections were steadily
administered with a 21-gauge 1.5 latex-free needle inserted into the skin fold. Rats were
returned to their cage after injections and monitored until full recovery.

3.6

Animal Necropsy and Cranium Harvesting
Three rats per group were sacrificed at 3 months and 4-5 rats per group were

sacrificed at 6 months for fluorescence, radiological, and histological assessments. These
time points are consistent with the normal duration of bone remodeling in humans (1). At
necropsy, all animals were euthanized according to Duquesne University IACUC
protocols. Animals were first deeply sedated with 4 – 5% isoflurane. After the absence
of reflexes was verified, the animals were placed securely in the decapitation apparatus
and the head removed completely. Whole heads were immediately transferred to ice-cold
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10% buffered formalin and stored at 4oC for 48 hours. After fixation, skin and muscle
tissue were carefully trimmed and removed from the cranium. The skulls were cut
transversely into superior and inferior halves and the brain carefully removed. The
superior skull bone was stored in 70% ethanol until further processing could be
completed.

4.

Radiography and Histology

4.1

Radiograph Imaging and Processing
Prior to sectioning, superior aspect radiographs were taken of each skull to

document radiographic density at the defect site. Radiographs of defect areas are
routinely used to assess bone repair and the quality of bone that fills the defect site (13).
Radiographs were digitally equilibrated to reduce variability between backgrounds (XRay Copy Service, North Huntington, PA). Radiographic intensity was quantified from
the superior aspect of the implant surface and normalized to background intensity using
NIH Image J software. Radiographs were quantified as follows:
1. Open image in NIH Image J
2. Image > Type > 16 bit
3. Analyze > Set Scale > 100 pixels = 1 arbitrary unit (AU)
4. Analyze > Set Measurement > Check: Integrated Density
5. Using the box tool, create a box size 0.5 x 0.5 AU over film background
6. Analyze > Measure (This value is background intensity)
7. Move the same box over the center of the scaffold using the arrow keys
8. Analyze > Measure (This value is the scaffold intensity)
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9. For normalization, scaffold intensity was divided by the background
intensity

4.2

General Histology and Fluorescence Microscopy
Sectioning, staining, and digital photographs of 3 month histology and 3 and 6

month fluorescence were completed at the Center of Metabolic Bone Disease, University
of Alabama (P.F.L.). The area of interest, defined as a coronal section approximately
centered inside the defect site, was brought to the surface through preliminary grinding.
Afterwards, samples were cut to 100 µm (Exakt Diamond Saw, Exakt Technologies Inc.,
Oklahoma City, OK) and then ground to 20-30 µm sections (Exakt Grinding System,
Exakt Technologies Inc., Oklahoma, OK). Ground sections were either stained for
histology or left unstained for fluorescence microscopy. Stained sections were treated
with a dibasic stain of 0.03 M methylene blue/ 0.018 M basic fuchsin to highlight cellular
proteins (e.g., bone, collagen, and connective tissue) and DNA. This method is reported
to provide vivid contrast between the cellular and connective tissue elements in tissue
sections with results similar to a hematoxylin-and-eosin procedure (120). Methylene blue
is a basic stain (i.e., positively charged) used to highlight the cell nucleus because it is
attracted to the negative charge of nucleic acid chains (e.g., phosphate backbone in
DNA). Unlike ethidium bromide, it is safer and will not intercalate into the DNA strand.
Basic fuchsin is also a basic dye with a positive charge that is applied after excess
methylene blue is washed away. Connective tissues, specifically collagen, are
highlighted blue-purple, while cell cytoplasm develops a pink-to-purple coloration (120,
121). Digital images of stained 3 month histology and unstained 3 and 6 month
49

fluorescence were captured with an Olympus BX51 microscope equipped with a QImaging camera with an Olympus MWBV2 Wideband Blue wavelength filter. Multiple
digital photographs of stained and unstained sections were spliced together to create a
montage of the complete skull section using Bioquant Image Analysis software. Digital
images of stained 6 month histology were captured on an Olympus BX40 microscope
using an Olympus DP70 camera and DP Controller software. This imaging was
completed at Duquesne University and the images were not spliced together to create
montages. Quantification of fluorescence within and surrounding the scaffold was
completed using NIH Image J software as follows:
% Fluorescence and Number of Fluorescent Regions
1. Open image to be analyzed in NIH Image J
2. Process > Subtract background > Set pixels to 50.0 (default)
3. Image > Brightness/Contrast > Auto
4. Image > Color > Split Channels (Close all channels except for Green
Channel)
5. Image > Adjust > Threshold > Check Dark Background
6. Set threshold to overlap actual fluorescence as closely as possible (red
coloration)
7. Process > Smooth
8. Highlight around scaffold with Box tool
9. Analyze > Set Measurements > Check: Area, Area Fraction, Limit to
Threshold, Display Label > OK (% Fluorescence)
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10. Analyze > Analyze Particles > Check: Pixel Units and Summary; Size: 0infinity; Show: Outlines > OK (No. of Fluorescent Regions)
Fluorescent Intensity
1. Follow above protocol to Process > Smooth
2. Highlight around scaffold with Box tool
3. Analyze > Set Measurements > Check: Integrated Density > OK
4. Analyze > Measure

5.

Statistics
The statistical interaction between group means for each time point and treatment

group was analyzed by a two-way ANOVA. The two-way ANOVA helps to determine if
several population means are statistically different when evaluating two independent
variables (e.g., treatment and time). A Bonferroni method was chosen for the post-hoc
test given its fairly powerful nature and the planned (a priori) comparison of pairs of
experimental groups. The effect of treatment groups at individual time points (i.e., main
effect) was analyzed by a one-way ANOVA with a Bonferroni post-hoc test. Analyses
were performed using GraphPad Prism 5.0® software. A p-value of less than 0.05 was
considered significant.
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RESULTS
Preliminary Data
The following data was collected by Rachelle Palchesko and Jared Romeo of Dr.
Galwalt’s laboratory. Analytical assessments were conducted to verify the
reproducibility and accuracy of the chemical attachment of melatonin to the CA surface
(Fig 8A). Calcium aluminates modified with a chemical linkage to the melatonin
molecule were analyzed using Diffuse Reflectance Infrared Fourier Transform (DRIFT)
spectroscopy. DRIFT analysis indicates that both 12-bromododecanoic acid (linker) and
melatonin were attached in consecutive steps to the CA surface (Figs 8B and 8C,
respectively). Functionality of this linkage was determined through other assessments.
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Figure 8. Chemical Linkage of Melatonin to the Calcium Aluminate Surface is
Accomplished Using Simple Linker Chemistry
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Figure. 8. Synthesis and confirmation of melatonin linkage on calcium aluminate surface. (A)
Melatonin is attached to the calcium aluminate surface through a two-step deposition process
using 2mM 12-bromododecanoic acid and 1 mg/mL melatonin/1% pyridine solutions. (B) Diffuse
Reflectance Infrared Fourier Transform (DRIFT) spectroscopy produced peaks at 2918 cm -1 and
2850 cm-1 confirming the attachment of bromododecanoic acid to the calcium aluminate surface.
(C) DRIFT spectroscopy produced peaks at 1215cm -1 and 1175cm-1 confirming the attachment of
melatonin to the calcium aluminate surface.

Preliminary experiments were conducted in vitro to determine the viability of
normal human osteoblasts (Nhosts) and NIH 3T3 fibroblasts on unmodified (CA) and
modified (CA-Mel) scaffolds. The determination of cell viability by live/dead assay was
conducted at day 1, 4, and 7 in culture (Fig. 9A). The number of viable fibroblasts was
significantly reduced on CA-Mel scaffolds on days 4 and 7 (p < 0.001, Fig. 9C, D)
suggesting that the presence of surface melatonin molecules affects fibroblast viability.
The number of viable osteoblasts was significantly increased on CA-Mel scaffolds for all
time points (Fig. 9B-D; p < 0.001). Moreover, viable osteoblasts were significantly
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greater at all time points when compared to viable fibroblasts on modified scaffolds (Fig.
9B-D; p < 0.001), with the greatest difference at day 7 (Fig. 9D; p < 0.001). These
findings suggest a preference of normal human osteoblasts for viability on the scaffolds
where melatonin had been attached. Further, viability of osteoblasts on both scaffold
types supports the biocompatibility of calcium aluminate with this mature cell type.

54

Figure 9. Normal Human Osteoblast and NIH 3T3 Fibroblast Viability is Differentially
Affected by CA Scaffold Surface
NIH 3T3 Fibroblasts
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Figure 9. Calcium aluminate scaffolds functionalized with melatonin demonstrate a preference for
normal human osteoblast adherence and proliferation over 7 days in culture when compared to
unmodified (CA) and modified (CA-Mel) scaffolds seeded with NIH 3T3 fibroblasts and
unmodified scaffolds seeded with normal human osteoblasts. (A) Cell viability on scaffold
surfaces was assessed by live/dead fluorescence at the time points indicated and representative
photos are shown. Green fluorescence indicates live cells, red fluorescence indicates dead cells.
Magnification = 10x. (B-D) Live cells were averaged from 5 separate fields of view for each
scaffold type at 1, 4, and 7 days in culture. Unmodified and modified CA surfaces demonstrate a
preference for Nhost versus NIH 3T3 fibroblast viability at all time points (p < 0.001) with the
greatest preference seen on surfaces modified with melatonin (p < 0.001 for all time points).
Modified scaffolds significantly reduce NIH 3T3 fibroblast viability over unmodified scaffolds at
days 4 and 7 (C and D, respectively; p < 0.001 for both). Viability of NIH 3T3 fibroblasts on
unmodified or modified CA surfaces is not significantly different on day 1 (B). Group averages
were statistically analyzed using a One-way ANOVA with a Bonferroni post-hoc test. n = 9
scaffolds per group for each time point. Photographs and quantified data courtesy of Rachelle
Palchesko and Jared Romeo.
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Specific Aim One
Assess the effects of unmodified (CA) and modified (CA-Melatonin) scaffolds on human
adult mesenchymal stem cell (hAMSC) differentiation and morphology in the presence
and absence of PRP.

The ability of unmodified and modified scaffolds to induce osteogenic
differentiation of hAMSCs was examined at 7 and 14 days by assessing alkaline
phosphatase activity, a known marker of osteoblast differentiation and activity, in
osteogenic medium (OS+). Osteogenic medium provides as stimulus to hAMSCs that
favors differentiation versus proliferation. The exposure of hAMSCs to osteogenic
medium slows their proliferation and promotes their differentiation into an osteoblast
lineage as exemplified in Fig. 6. These time points have been shown to be specific to
heightened hAMSCs differentiation and alkaline phosphatase activity (67, 68, 72).
Alkaline phosphatase (ALP) staining after 7 and 14 days in osteogenic medium appears
more abundant on unmodified CA scaffolds compared to scaffolds modified with
melatonin (Fig. 10B). However, the presence of ALP staining in the CA-Mel group
suggests melatonin remains functionally active when attached to the CA surface and may
delay the differentiation of hAMSCs into an osteoblast lineage. The linkage to the
nitrogen in the indole ring leaves both side arms of the molecule free from constraints. As
such, the methoxy and N-acetyl groups may freely interact with receptors in hAMSCs to
induce their differentiation. Although not fully investigated in this study, the application
of specific inhibitors could be considered in the future to determine receptor-dependent
activity. Indeed, ALP activity appears to increase with an increased duration of exposure

56

to melatonin in osteogenic medium (Fig. 10B). Interestingly, hAMSCs cultured on the
unmodified CA surface underwent differentiation in basal (OS-) medium lacking
osteogenic supplements (Fig. 10A). This could suggest that the CA material alone has
inherent capabilities of stimulating differentiation that may further enhance
differentiation over that of modified CA groups when in the presence of osteogenic
medium.
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Figure 10. Human Adult Mesenchymal Stem Cell Differentiation is Supported on Both
Unmodified and Modified CA Surfaces
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CA-Mel

CA
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CA

Osteogenic Medium (OS+)

Figure 10. Human adult mesenchymal stem cell differentiation occurs on both unmodified and
modified CA surfaces. The effect of CA scaffolds on hAMSC differentiation into osteoblasts was
assessed qualitatively by the presence of alkaline phosphatase after 7 and 14 day incubation in
(A) basal (OS-) and (B) osteogenic (OS+) media. (A) Alkaline phosphatase activity, as indicated
by red staining, was not observed for CA-Mel groups in basal media, suggesting osteogenic
supplements facilitate melatonin-induced hAMSCs differentiation. (B) Alkaline phosphatase
activity increases from day 7 to day 14 on both unmodified and modified scaffolds. Images
recorded at 10x; scale bars measure 2 mm.

Scanning electron microscopy was utilized to investigate hAMSC morphology
and migration on unmodified and modified CA surfaces (Fig. 11). The hAMSCs
cultured on unmodified surfaces are elongated and plate-like, a sign of intracellular
cytoskeletal rearrangement associated with adhesion and differentiation into an osteoblast
lineage (122). The majority of hAMSCs cultured on CA surfaces modified with
melatonin exhibited a rounded morphology, although occasional elongated cells were
also present (Additional pictures in Appendix). Whether or not the rounded morphology
of hAMSCs cultured on modified surfaces affects processes of differentiation remains to
be determined. Exposure to melatonin by this delivery method may delay the
differentiation of hAMSCs into mature osteoblasts when cultured on modified surfaces.
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CA surfaces without the presence of hAMSCs were not analyzed in the current study but
may benefit future comparisons and aid in distinguishing extracellular matrix material
from cellular components. Nonetheless, these in vitro studies could highlight important
effects of culture conditions (i.e., 2-dimensional versus 3-dimensional) and melatonin
delivery methods (i.e., exogenous administration versus immobilization) on hAMSCs
differentiation when cultured on CA scaffolds. Physical (e.g., clotting) and chemical
(e.g., signaling responses) barriers created by the addition of PRP limited the
experimental analysis that could be conducted for PRP-treated groups in culture. These
limitations will be addressed in later sections. Optimization of culture methods for
experimental groups containing PRP are warranted for future investigation.
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Figure 11. Morphological Assessment of hAMSCs Cultured on Unmodified and Modified
CA Surfaces
CA
CA-Mel
Pore

Day 7

Day 14

Figure 11. Modified CA surfaces affect hAMSC morphology. hAMSCs grown on CA surfaces
modified with melatonin exhibit a rounded morphology that may indicate a more migratory nature
at both 7 and 14 days in culture (black arrows). hAMSCs grown on unmodified CA surfaces
exhibit an elongated, flattened morphology associated with cytoskeletal reorganization for
adhesion and differentiation at both 7 and 14 days in culture (white arrows). Imaging was
completed on a Hitachi S-3400N-II Variable Pressure scanning electron microscope under
vacuum. Representative images are shown. Scale bars measure 500 µm.

Specific Aim Two
Assess the effects of unmodified (CA) and modified (CA-Melatonin) scaffolds on bone
formation and remodeling activity in the presence or absence of PRP in a rodent model
of calvarial defects.

Bone removal in the calvaria defect model was the most critical aspect of this
procedure as the morbidity and mortality rate is usually high with this step. No animals
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suffered neurologic symptoms following partial frontal bone removal and animal
mortality associated with the surgical procedure was approximately 10% (of 33 animals).
Animal recovery was uneventful with no signs of local infection, lingering algesia, or
abnormal body weight fluctuations. The use of the Piezotome™ for bone removal likely
contributed to reduced group mortality and defect morbidity. Histology and radiology of
the defect site revealed that some of the implants had shifted away from the original
defect site during healing in a few animals. These animals were not excluded from the
following assessments given the close proximity of the implant to the original osteotomy
site and the importance of gathering information about the osteoinductive nature of the
biomaterial.
Before sectioning, radiographs of each skull were recorded to determine
qualitative and quantitative changes in bone and/or scaffold density at the implant site.
Radiograph films were digitally equilibrated to reduce the variability of background
correction (Fig. 12A). There was no significant difference in the radiographic intensity
between treatment groups at 3 or 6 months (Fig. 12B). However, the overall radiographic
intensity of all groups increased significantly with time between the 3 month (1.26 ±
0.03) and 6 month (1.36 ± 0.04) time points (p = 0.0359) as would be expected with
normal healing. Radiographs may have been a limited assessment of bone formation in
experimental groups given that they only detect superficial changes on the most superior
aspects of the scaffold surface. Thus, histological and fluorescence assessments of
calvarial bone sections were used to gain a more detailed look at bone remodeling
activity and bone formation between groups.
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Figure 12. Radiographic Intensity of the Superior Aspect of Unmodified and Modified
CA Surfaces is Significantly Increased Over Six Months
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Figure 12. Radiographic intensity at calvarial defect sites is significantly increased between three
and six months. (A) Representative superior skull radiographs for three and six month time
points. Included is a radiograph of an empty defect site to illustrate that these defects will not
spontaneously heal by six months. (B) Radiographs were digitally equilibrated to reduce
background variability and quantification of radiographic intensity was normalized to
background intensity. The effect of time on group means was statistically significant (3 mo: 1.26
± 0.03 versus 6 mo: 1.36 ± 0.04; p = 0.0359); however, treatment and the interaction between
treatment and time were non-significant. Bars represent mean ± SEM. Black dashed line
represents the range of radiographic intensity for empty defect sites. Solid white arrow
indicates empty defect site. Dashed white arrow indicates CA scaffold seated in defect site.
Groups were compared via a Two-way ANOVA with Bonferroni post hoc test. n = 3 - 5.

Unstained histological sections from each experimental group were visualized
with fluorescence microscopy to assess the incorporation of the injected fluorochromes as
an indication of active bone remodeling. Qualitative assessments suggest that the CAMel group may have a higher degree of bone remodeling activity when compared to the
other treatment groups (Fig. 13A). To support qualitative observations, the percentage of
scaffold fluorescence, fluorescent intensity, and the number of fluorescent regions were
quantified from double-labeled sections (Fig. 13B-D). The degree of scaffold
fluorescence was significantly greater for the CA-Mel group at three months compared to
the CA or CA + PRP groups (p < 0.05 for both; Fig. 13B). Likewise, a significantly
greater percentage of scaffold fluorescence was noted for the CA-Mel group at six
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months compared to all other groups (p < 0.01; Fig. 13B). Fluorescent intensity was
significantly greater for the CA-Mel group at three months when compared to the CA +
PRP group (p < 0.05) and at six months when compared to all other groups (p < 0.05 for
CA and CA-Mel +PRP; p < 0.01 for CA + PRP; Fig. 13C). The number of fluorescent
regions was found to be significantly greater for the CA-Mel group at six months when
compared to other experimental groups (p < 0.01 for CA and CA + PRP; p < 0.001 for
CA-Mel + PRP; Fig. 13D). This suggests that the CA-Mel implant may significantly
impact the degree, intensity, and abundance of osteoid tissue mineralization and bone
formation in this model. Analysis of scaffold fluorescent intensity for the unmodified
group (CA) in the absence of PRP at three and six months by an unpaired t-test revealed a
significant decrease at six months (p = 0.0155). Further, increased sites of internal
mineralization suggest melatonin may facilitate migration of cells into the scaffold
interior. The time between three and six month assessments did not significantly impact
the effect of any treatment. It may be that the peak of melatonin activity is reached at
early time points and maintained at a plateau level or that the time interval between three
and six months is not long enough to detect a significant change. The addition of PRP
did not significantly improve these parameters alone or in conjunction with melatonin
suggesting the temporal regulation of chemical cues for proliferation and differentiation
may need to be adequately separated in order to see a synergistic effect in the
combination group.
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Figure 13. Scaffolds Modified with Melatonin Augment Bone Remodeling Activity In
Vivo
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Figure 13. The effect of unmodified (CA) and modified (CA-Mel) scaffolds on bone remodeling
activity in calvarial defects in ovariectomized Sprague-Dawley rats was assessed by
fluorochrome incorporation (A) and quantifiable characteristics from fluorescent
photomicrographs (B-D). Double-fluorochrome labeling at three and six months is more robust in
the CA-Mel group. These observations are confirmed by quantification, showing that CA-Mel
scaffolds have a greater degree (B), intensity (C), and abundance of bone remodeling activity
when compared to other experimental groups. Time and the interaction between time and
treatment were not statistically different. Bars represent means ± SEM. * indicates significance,
p < 0.05; ** indicates significance, p < 0.01; *** indicates significance, p < 0.001 by two-way
ANOVA with Bonferroni post hoc test. Three and six month photomicrograph montages prepared
from 4x magnification. n = 3 - 5.

A methylene blue/basic fuchsin stain was used to examine general histology of
the defect site and the implant circumference for signs of tissue ingrowth and osteoid
synthesis along the scaffold surface. This method is reported to provide vivid contrast
between the cellular and connective tissue elements in tissue sections with results similar
to a hematoxylin-and-eosin procedure (120). Methylene blue is positively charged, basic
dye used to highlight the cell nucleus because it is attracted to the negative charge of
nucleic acid chains (e.g., phosphate backbone in DNA). Basic fuchsin, also a positively
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charged, basic dye, highlights connective tissues. Connective tissues, specifically
collagen, are highlighted blue-purple, while cell cytoplasm develops a pink-to-purple
coloration (120, 121). Review of the stained sections at the three month time point
indicates that the implanted scaffolds provide a favorable surface for the growth and
incorporation of cells and connective tissues (Fig. 14A). In some cases, implanted
scaffolds shifted away from the defect site and were located over intact bone (Fig. 14A;
CA and CA+PRP at 6 months). Interestingly, early histological assessments provide
evidence of the degradation of the calcium aluminate scaffold along the implant border
(Fig. 14A). Regions of interest from experimental groups were noted and viewed under
higher magnification. Defect sites implanted with CA-Mel with and without PRP
showed signs of scaffold integration, tissue infiltration into scaffold pores, and osteoid
synthesis along the scaffold surface (Fig. 14B). Many of the cells that were present
around the implanted scaffolds at 3 months had subsequently been replaced by bone
matrix tissues (e.g., parallel bands of collagen or lamellar bone attachments) (Fig. 14B),
indicative of the normal bone repair process. Thus, the cells noted in the 3 month
photomicrographs may be cell types associated with the early stages of bone remodeling
such as osteoprogenitor cells or those associated with osteoid synthesis and
mineralization such as osteoblasts, as other cell types such as fibroblasts would not
contribute to bone remodeling. This is further supported by the preference of the calcium
aluminate material for osteoblasts versus fibroblasts noted in the preliminary studies (Fig.
9) and the qualitative and quantitative results from the double-labeled sections (Fig. 13AD). Signs of tissue infiltration or attachments from the defect border were not noted in
the unmodified group with or without PRP (CA+ PRP and CA, respectively). Instead,
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open space filled with fine connective tissue was observed (Fig. 14B). Furthermore,
because the fluorescence around and through the scaffolds overlaps the cells and proteins
depicted by the histological stain and the quantification of fluorescence was averaged
from 3 – 5 animals per group, the fluorescence noted in the photomicrographs is not a
result of artifacts from the staining or visualization procedures.
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Figure 14. Unmodified and Modified Scaffolds are Osteoconductive and Biocompatible
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Figure 14. Histological evidence of the biocompatibility and potential biodegradation of the
calcium aluminate material in experimental groups. (A) Early (3 month) and late (6 month)
histological sections stained for cellular proteins (e.g., bone, collagen, and connective tissue;
pink/purple) and DNA (e.g. cell nucleus; blue/dark purple) indicate that implanted scaffolds
provide a favorable surface for the growth and incorporation of cells and connective tissues. (B)
Regions of interest from select experimental groups at six months were viewed under higher
magnification. Defects sites implanted with CA-Mel with and without PRP showed signs of
scaffold integration, tissue infiltration into scaffold pores, and osteoid synthesis along the scaffold
surface. Three month photomicrograph montages prepared from 4x magnification. Six month
photomicrographs captured at 10x; scale bars measure 2 mm. Regions of interest for 6 month
photomicrographs captured at 200x; scale bars measure 200 µm. S = Scaffold, B = bone at
defect edge, P = scaffold pore, arrow = lamellar attachments. n = 3 – 5.

Overall, melatonin was successfully linked to CA surfaces using simple chemical
methods carried out at room temperature. Both unmodified and modified CA scaffolds
were found to be biocompatible in in vitro and in vivo environments. Scaffolds modified
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with melatonin demonstrated a preference for the adhesion and proliferation of normal
human osteoblast but may delay the differentiation of hAMSCs. These results may have
contributed to the enhanced bone remodeling activity in calvarial defects of animals
implanted with modified CA scaffolds. The application of PRP confounded in vitro
analyses and had negligible impact on bone remodeling in vivo, both alone and when
combined with melatonin. Radiographic intensity of the defect site increased over time
for all experimental groups. Although signs of biodegradation were observed, both
unmodified and modified CA scaffolds provided osteoconductive surfaces out to six
months. Mechanisms regulating the recruitment, attachment, and activity of hAMSCs
and mature osteoblasts may underlie the effects of melatonin on bone formation when
immobilized on CA surfaces.

DISCUSSION
1.

Study Summary
Bone possesses inherent capabilities of regeneration in response to adult

development and traumatic injury. The process of bone regeneration involves the
orchestration on several spatially and temporally regulated events mediated by specific
signaling cascades and cell-cell interactions. In the majority of cases, the new bone will
have largely restored its native mechanical and physiological properties and be relatively
indistinguishable from adjacent uninjured bone (123). Nonetheless, there are cases where
total bone regeneration is impaired either by exceeding the normal regenerative capacity
of the bone (e.g., large bone defects created by trauma, tumor resection, or skeletal
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abnormalities), or in cases where the normal regenerative capacity is compromised (e.g.,
osteoporosis) (123).
Despite a wide variety of methods for treating impaired bone regeneration, current
tissue engineering strategies aim to regenerate native bone tissue without the
disadvantages associated traditional autogenic or allogenic bone grafts. While the
limitations associated with traditional bone grafting methods have driven the
development of synthetic substitutes, no synthetic bone material currently available
exceeds or matches the biological or mechanical properties of native bone tissue (123).
Thus, there is significant impetus to recapitulate the biological and mechanical properties
of human bone tissue in a cost-effective and safe manner through the development of
bioactive bone substitutes that contain growth factors and/or osteoprogenitor cells for
guided bone regeneration. The goal of the current study was to optimize the bone
regenerating properties of calcium aluminate (CA) scaffolds by exploiting their potential
as carriers of therapeutic agents that could locally direct and facilitate new bone
formation. Histological, radiological, and mechanistic analyses were utilized to evaluate
the osteoconductive and osteoinductive properties of unmodified (CA) and modified
(CA-Mel) scaffolds in the presence or absence of growth factor-rich platelet-rich plasma
(PRP) as well as their biocompatibility with a variety of cell types common to the bone
remodeling process. Specifically, a rodent model of calvarial defects was employed to
investigate the effect of locally delivered melatonin and/or PRP in combination with the
CA biomaterial on new bone formation.
This study reports an effective way of attaching melatonin to customizable CA
scaffolds using simple linker chemistry carried out at room temperature (Fig. 8). Post-
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operative healing in experimental groups was uneventful, with the implanted materials
producing no signs of inflammation, infection, or inducing detectable behavioral changes.
The biocompatibility of the CA material was additionally supported by histology (Fig.
14) and external in vitro testing (Figs. 9 and 10). The chemical linkage of melatonin to
CA significantly increased the degree, intensity, and abundance of bone remodeling
activity in critical-size calvarial defects in ovariectomized rats (Fig 13). These findings
may be attributed to the preference modified (CA-Mel) scaffolds demonstrated for the
proliferation and adhesion of normal human osteoblasts (Nhosts) (Fig. 9) and their
support of human adult mesenchymal stem cell (hAMCS) differentiation (Fig. 10).
Modified scaffolds may delay hAMSC differentiation, which increases with the duration
of culture in the presence of osteogenic medium (Fig. 10) and may promote a more
migratory phenotype in surface hAMSCs (Fig. 11). The inclusion of PRP upon
implantation appears to have negligible effects or to attenuate melatonin-induced effects
on bone remodeling activity in vivo (Fig. 13). Radiographic data regarding the density of
newly formed bone shows a significant increase over time in all groups (Fig. 12). The
absence of a detectable decrease in density suggests that the apparent biodegradation of
CA scaffolds (Fig. 14) is balanced with processes of bone formation (Fig. 13). Likewise,
both unmodified and modified CA scaffolds continue to provide an osteoconductive
surface out to six months (Fig. 14). Taken together, in vivo and in vitro results suggest
CA scaffolds modified with melatonin may enhance bone remodeling activity in calvarial
defects through hAMSC differentiation and recruitment, and a preferential effect on the
viability and function of mature osteoblasts.
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2.

Calcium Aluminate Synthesis & Modification
Stainless steel, titanium, cobalt-chromium, nickel, and their alloys are all

examples of metallic implants. The rigid nature of metallic biomaterial enhances their
strength characteristics making them better suited for the repair and reconstruction of
high impact regions. However, their rigid physical structure prevents the customization
of the implant to suit defect size and volume. Moreover, the inertness of metallic
implants limits the chemical bonding between the bone/implant interface due to the
passive oxide layer that forms on their surface (124). This oxidized layer is resistant to
further chemical reactions, confounding the ability to attach organic molecules (125).
Chemical attachment to titanium surfaces through common silanization methods are
hydrolytically unstable, leaving little protection of the bound molecules from aqueous
reactions (126). Recent engineering approaches have sought to enhance the proliferation
and adhesion of osteoblasts and bone formation by creating different roughness patterns
and surfaces for chemical attachment (126-128).
The nature of calcium-based ceramics is much less rigid than metallic devices,
and thus, allows them to be molded to fit distinct defect shapes and sizes. Their
crystalline structure provides some control over porosity during synthesis which benefits
osteointegration (129). While high heat treatments can reinforce the crystalline structure
and give strength to the material, it limits their functionalization (130). Moreover, many
calcium-based ceramics remain brittle and require stabilization when used in regions of
high impact (31, 33).
Physical analyses of the CA material conducted in other laboratories found that
normal sterilization procedures (121oC and 18psi of steam for 60 minutes) did not affect
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the porosity of the material and interestingly, enhanced mechanical integrity (105). In
this study, scaffolds of calcium aluminate were prepared by mixing the reactants with a
small amount of water. There were several advantages to this process including (i) the
CA material remains moldable for an extended period of time, (ii) porosity can be
controlled, and (iii) the resulting cast will develop and exhibit high mechanical strength at
room temperature (105). Structure formation at room temperature is especially important
for functionalization of biological agents to the scaffold surface. Thus, there are several
attractive properties of calcium aluminate with regard to its synthesis and mechanical
properties that support its potential use as a bone substitute material.

Ceramic materials, by nature, are only osteoconductive (37); however, the
inclusion of osteoinductive factors can be used to promote the differentiation of stem
cells into osteoblasts or augment osteoblast activity (29). Bone ingrowth into CA
scaffolds in calvarial defects at four weeks was reported to be negligible (50) and was not
typical of calvarial defect sites at six months (49). Thus, a chemical method to link
biological molecules to the CA surface to locally stimulate osteoinduction was
investigated here.
Locally delivered agents provide several advantages such as reducing systemic
side effects and producing a higher concentration of drug at the target site (130).
Methods of local delivery can include adsorption or covalent immobilization. Adsorption
is the non-specific physical interaction between a biomolecule and a biomaterial surface
(131). While this method is simpler, less disruptive to the biomolecule, and cheaper, it is
often a weak association that can be disturbed by temperature, pH, and other factors
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(131). Covalent techniques can be used to more permanently affix the biomolecule to the
biomaterial surface (131). Chemical methods in this study use the free end of organic
linkers covalently bound to the CA surface as a reactive location for the attachment of
other chemical and biological entities (131). The covalent immobilization of
biomolecules to biomaterial surfaces addresses many of the challenges associated with
the exogenous delivery of growth factors including the control of growth factor diffusion
and dosage (132, 133). Biomolecule immobilization is relevant to physiological models
as immobilized growth factors occur naturally, either sequestered in the extracellular
matrix or directly bound to cell surface binding moieties or intermediary molecules (132).
Other previously collected data suggest that the organic acid linkers of the CA
surface are not disrupted by chemical (i.e., solvent rinses) or mechanical (i.e., sonication)
means (134). Diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy was
used to verify the attachment of both the organic linker and melatonin molecule during a
two-step chemical deposition process (Fig. 8A). DRIFT analysis confirmed the
attachment of melatonin to the organic linker by spectral peaks representative of chemical
moieties associated with each substrate (Figs. 8B and C, respectively). Thus, the
chemical methods described in this study can be used to attach biomolecules to the CA
surface with the intent to locally deliver them to specific target sites. As discussed in
later sections, the functionality of CA-melatonin linkages was also confirmed.
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3.

In Vitro Biocompatibility of Unmodified & Modified Calcium Aluminate

Scaffolds
3.1

Effect of Unmodified & Modified Calcium Aluminate Scaffolds on Normal

Human Osteoblast & NIH 3T3 Fibroblast Viability
Preliminary aims of the study examined the effect of unmodified and modified
CA surfaces on the mature, non-transformed cell types, normal human osteoblasts
(Nhosts) and NIH 3T3 fibroblasts. Osteoblasts are the main bone forming cells of the
body and function to mineralize the bone matrix to impart strength (1). Fibroblasts are
common cells of connective tissues and function to synthesize extracellular matrix and
collagen (135). As such, they have critical roles in wound healing (135). Unmodified
CA aluminate surfaces supported the viability and proliferation of both cell types,
confirming results from acute toxicity testing revealing that CA lacks cytotoxic effects
(48). Interestingly, CA surfaces modified with melatonin enhanced the proliferation and
viability of Nhosts (Fig. 9). These findings are supported by work conducted by Nakade
et al. demonstrating that exogenous melatonin at doses between 50 and 100 µM enhanced
the proliferation of normal human bone (HOB-M) cells and human osteoblastic (SVHFO) cells (75). Conversely, melatonin appeared to reduce the proliferation and viability
of NIH 3T3 fibroblasts over time (Fig 9). Hypertrophic scar tissue is formed by the
abnormal proliferation of fibroblasts and excessive deposition of extracellular matrix
(136). Melatonin receptors are expressed at greater levels in fibroblasts from human
hypertrophic scars than normal human dermis (137). In studies of NIH 3T3 fibroblasts
transfected with human MT1 or human MT2 receptors, melatonin pretreatment reduced
proliferation and transformation (138). A reduction in fibroblast proliferation would be
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especially important in wound healing as the accumulation of fibrous connective tissue
can limit bone union (139). Taken together, these results suggest that the presence of
melatonin can preferentially affect cell viability. Thus, chemical modification of CA
surfaces with melatonin may be a valuable tool in directing cellular fate in bone
regeneration models. Likewise, these results suggest that the chemical attachment of
melatonin to the CA surface does not render the molecule biologically inactive.

3.2

Effects of Unmodified & Modified Calcium Aluminate Scaffolds on Human

Adult Mesenchymal Stem Cell Viability, Differentiation, & Morphology
Based on the viability studies supporting the preferential functionality of the
melatonin linkage, it was assumed that melatonin-induced effects on the differentiation of
hAMSCs would also be apparent. The pluripotent nature of mesenchymal stem cells
(MSCs) allows them to differentiate into several different lineages. The chemical cues
that drive mesenchymal stem cells toward an osteoblast phenotype can be replicated in
vitro by supplementing basal medium with dexamethasone, β-glycerophosphate, and
ascorbic acid (67, 68, 72). The differentiation of hAMSCs is further enhanced by the
exogenous administration of 50 nM melatonin (67, 68, 72). The most appropriate
treatment method for enhanced differentiation and calcium deposition was reported to be
the continuous administration of 50 nM melatonin every other day for a period of 21 days
(68). However, the effect of immobilized melatonin on hAMSCs differentiation has not
been reported. Thus, unmodified and modified CA scaffolds were seeded with hAMSCs
to determine the functionality of the melatonin linkage compared to control surfaces and
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to evaluate the specific time point(s) where hAMSCs transition into bone-forming
osteoblasts by this delivery method.
The effect of unmodified and modified CA surfaces on the differentiation of
hAMSCs into an osteoblast lineage was qualitatively assessed by ALP staining (Fig. 10).
An increase in the exposure of hAMSCs to surfaces modified with melatonin resulted in
increased differentiation in the presence of osteogenic medium suggesting that the
presence of melatonin does not negatively affect, but may delay, this process (Fig. 10B).
It has been hypothesized that melatonin-induced differentiation occurs when unique
protein scaffolds containing extracellular signal-regulated kinase 1/2 (ERK1/2), the
melatonin receptor (MT2), and β-arrestin are localized to the cytosol (68). These
complexes control the translocation patterns of ERK 1/2, a known modulator of cell fate,
to facilitate cellular differentiation versus proliferation (cytosolic localization versus
nuclear localization, respectively) (140). Moreover, ERK 1/2 is localized to the cytosol
when melatonin-induced ALP activity is highest (68), which supports the notion that
localization of ERK 1/2 in the cytosol promotes differentiation rather than proliferation.
These same mechanisms may have been occurring in this study, although not fully
investigated. In the future, culturing experiments on unmodified and modified CA
surfaces should incorporate the use of non-specific and specific melatonin receptor
antagonists (i.e., luzindole and 4-PPDOT, respectively) to confirm the above mechanisms
regulating differentiation of hAMSCs by melatonin.
Interestingly, hAMSCs cultured on the unmodified CA surface underwent
differentiation in basal (OS-) medium lacking osteogenic supplements (Fig. 10A). These
findings may suggest that the chemical and physical characteristics of unmodified CA
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scaffolds may have played a role in promoting hAMSC differentiation. Evidence for this
phenomenon comes from a study designed by Castro-Raucci et al., in which a novel
calcium aluminate cement was compared against the gold standard dental cement,
mineral trioxide aggregate (MTA) with regard to osteogenic proliferation and
differentiation (141). Osteogenic cells harvested from the calvarial bone of newborn rats
demonstrated significant viability, proliferation, and differentiation on CA compared to
MTA (141). Likewise, although many calcium-based ceramics are not considered
osteoinductive, some calcium phosphate materials have produced ectopic bone formation
in the absence of osteogenic signals (35). It is suggested that the release of calcium ions
enhances the adhesion of osteogenic cells and osteoclasts (37). Early studies demonstrate
CA can release free calcium ions in the local area of the implant (142). Additionally, the
physical properties of a biomaterial can regulate tissue morphogenesis in a lineage
specific manner (143). For example, harder surfaces that mimic the mineralized bone
matrix favor mesenchymal stem cell differentiation into osteoblasts (143). Nanoscale
topography (i.e., nanoscopic physical characteristics) of biomaterial surfaces can increase
mesenchymal stem cell sensitivity to soluble signals and significantly enhance their
differentiation into osteoblasts (144). Pre-osteoblast cells from mouse calvarial bone
(MC3T3-E1) exhibited an increase in focal adhesion complexes and thick F-actin fiber
development, events consistent with differentiation, on “textured” nanoparticle-modified
surfaces compared to smooth glass surfaces (144). Evidence for this in the current study
may stem from hAMSCs differentiation that occurred on porous unmodified CA surfaces
in the absence of medium-based osteogenic signals. Osteogenic media is a requirement
for melatonin-induced increases in hAMSC differentiation (67) and is likely the reason
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why CA-Mel did not induce differentiation of hAMSC in basal media in the current
study. The inherent capability of unmodified CA scaffolds to promote hAMSC
differentiation requires further study.

Morphological assessment of unmodified and modified CA surfaces reveals two
distinct hAMSC morphologies (Fig. 11). Although both surfaces contained rounded and
flattened hAMSCs, the rounded phenotype was more commonly observed on the
modified CA surface. A flattened morphology is typical of adhesion and differentiation
processes while rounded morphology is a sign of contact inhibition that may indicate
cellular migration (122). The immobilization of melatonin molecules to the synthetic
surface through the described chemical modification may drive the migration of
hAMSCs, in particular, to regions of melatonin localization.
It has been reported that immobilized growth factors may also promote the
migration of cells across chemical gradients. Bioprinting is a technology that uses a
modified printing device to deposit biological materials in two- or three-dimensional
patterns. Recent studies involving the use of bioprinting have been designed to
investigate how cells react to spatial patterns of immobilized growth factors. A study by
Miller et al. found that mesenchymal stem cells will migrate across a fibrin meshwork
(i.e., bioprinting substrate) in response to heparin-bound epidermal growth factor-like
growth factor (HB-EGF) (132). Interestingly, the mesenchymal stem cells were equally
guided away from the cell source regardless of whether the immobilized growth factor
concentration was equivalent across the bioprinting substrate or if the concentration
followed a low-to-high concentration pattern (132). These results could indicate that
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simple uniform distributions of growth factors immobilized on extracellular matrix
material may be just as effective in directing cell migration as more complex patterns
with concentration gradients (132). In another study, recombinant VEGF-165 was
immobilized onto collagen sponge scaffolds using 1-ethyl-3-[3dimethylaminopropyl]carbodiimide hydrochloride (EDC) chemistry. The immobilized
VEGF-165 patch was used to drive the migration and proliferation of endothelial cells as
a means of promoting myocardial repair. The resulting greater angiogenic responses
from VEGF-165 patches contributed to improved cell survival and tissue formation
(145). The persistence of the immobilized growth factor pattern over time likely
contributes to a constant stimulus for cellular migration and proliferation in these studies.
Although the migration studies discussed above occurred on patterned, smooth,
planar surfaces, melatonin is known to have chemoattractant effects (146) and may have
similar effects on cell behavior in our model system. Thus, the chemical immobilization
of melatonin may stimulate cell migration and interaction between cell surface receptors
on hAMSCs and the immobilized molecule. While the distribution of melatonin
molecules is hypothesized to be equally distributed over the surface of the treated CA
(147), the concentration of molecules may be dependent on specific attachment points
which, in turn, may be dependent on specific topographic characteristics of the CA
surface. Those hAMSCs seeded in areas with adequate access to melatonin may have
undergone differentiation, while those established in areas of reduced melatonin access
would benefit from migration towards adequate concentrations. The motile nature of the
cultured hAMSCs on modified CA surfaces may be evident by their rounded
morphology, a sign of migration (122) (Fig. 11). Consequently, the time points for
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observing the differentiation effects of melatonin on hAMSCs may be altered as these
cells first migrate across the CA surface before adhering and undergoing differentiation.
If these observations are supported in future studies, the time points for melatonininduced differentiation, as detected by ALP induction, may proceed at time points that
follow hAMSC migration. It is also worth mentioning that initial inflammatory
responses in vivo after implantation may have facilitated the migration of both immature
(i.e., MSC) and mature (i.e., osteoblast) cells via chemotactic factors released from
immune cells such as macrophages including interferon-gamma (INF-γ), tumor necrosis
factor-alpha (TNF-α), and interleukins. Additional SEM analysis is required to fully
investigate the migration patterns of hAMSCs on both unmodified and modified surfaces.

4.

In Vivo Biocompatibility of Unmodified & Modified Calcium Aluminate
Scaffolds
The host response to biomaterials can vary widely based on the characteristics of

the host, material, and surgical procedure (124). In terms of biomaterials,
biocompatibility is difficult to define, but is loosely defined as “the ability to perform
with an appropriate host response in a specific situation” (124). This definition of
biocompatibility supersedes the traditional concept of biomaterial inertness, as many
newly developed biomaterials favor specific host responses (e.g., increased bone-forming
activity, vascularization, etc.) in order to optimize the performance of the device. Indeed,
it is now recognized that no biomaterial is completely inert in the human body, even the
most stable metallic implants (124). Thus, it was important to ensure that any benefit to
utilizing CA biomaterials for bone regeneration were outweighed by toxicity associated
80

with its components. Signs of inflammation, infection, or behavioral changes in animals
(e.g., reluctance to be handled, avoidance or aggressive behavior, changes in eating
habits) were not observed and all animals gained weight at a normal rate.

4.1

Osteoconductive Properties of Unmodified & Modified Calcium Aluminate

Scaffolds
The biocompatibility of the biomaterial in the host environment can directly
impact its osteoconductive nature. Osteoconductive properties of a biomaterial allow it
to serve as a suitable surface for cellular events, interactions, and the apposition of new
bone (29, 30, 153). Histopathological analysis was employed to examine the
osteoconductive nature of implanted unmodified and modified CA scaffolds in a calvarial
defect model including signs of cell migration and tissue infiltration. All experimental
groups support the growth and expansion of cells and tissues derived from the defect site
and the surrounding bone (Fig. 14A). Moreover, histological staining identified the
presence of immature connective tissues (i.e., osteoid) around the outer circumference of
the scaffold and lining scaffold pores (Fig. 14B).
Porosity is a hallmark of both trabecular and cortical bone. The morphology of
trabecular bone is 50-90% porous with pore sizes on the order of 1 mm in diameter (154).
Cortical bone is a relatively solid structure, but a series of Haversain canals results in a
porosity of 3-12% (154). Porosity of both native bone and scaffold biomaterials supports
the migration and proliferation of mesenchymal stem cells, osteoblasts, and osteoclasts as
well as the development of vasculature and new bone (130). Tissue infiltration further
aids the fixation of the implant in the local environment (124). The average pore size of
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the CA material utilized in this study is reported to be 100 µm (105, 147), which is
sufficient for cell migration and bone ingrowth (31). After seeding cells on calcium
aluminate surfaces with a pore size of 100 µm, Bose et al. found that some of the CA
material contained monolayers of human osteoblasts (155). Further, calcium aluminate
cylindrical pellets with larger pore sizes (100 – 150 µm and 150 – 200 µm) had
substantial bone ingrowth in canine femoral defects compared to smaller pore sizes (75 –
100 µm) that contained unmineralized osteoid tissue (154). Thus, the histological results
described in the current study confirm that CA materials with adequate porosity support
the infiltration of cells and tissues and that the size and interconnectivity of scaffold pores
plays an important role in these findings.

4.2

Osteoinductive Properties of Unmodified & Modified Calcium Aluminate

Scaffolds
The goal of this study was to create a synthetic bone substitute with regenerating
properties similar to natural bone including developing its osteoinductive properties to
facilitate osteointegration. While early in vitro studies and in vivo histology provide
evidence that both unmodified and modified CA surfaces are biocompatible with a
variety of cell types and support the development of connective tissues after implantation,
the enhancement of bone formation through osteoinductive modifications were also
considered and analyzed. To this end, the osteoinductive influence of modified CA
scaffolds in the presence or absence of growth factor-rich PRP was investigated in a
rodent model of critical-size calvarial defects based on the reported osteoinductive
properties of melatonin and PRP. Calvarial defects provide little bone peripherally
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around the implant and lack significant impact or weight-bearing forces that will
contribute to spontaneous bone regeneration. Thus, a calvarial defect model provides a
substantial challenge to the osteoconductive and osteoinductive properties of the
implanted material, as the major contribution to bone regeneration must come from the
scaffold, not the host bone (44, 156) .
Studies of bone marrow from rats and humans indicate that melatonin is
synthesized and stored locally in the bone tissue where it is twice as high as nighttime
levels in peripheral blood (76, 157). These findings suggest that local synthesis and
storage of melatonin in bone may be important for bone repair. Although, the topical
application of melatonin facilitated the osteointegration of dental implants in Beagle dogs
(74, 77-79) and rabbits (80), its delivery via a surface linkage to CA scaffolds has not
been tested in an appropriate model of bone repair. As mentioned before, DRIFT
analysis confirms that molecules of melatonin can be attached to the CA surface utilizing
simple linker chemistry (Fig. 8) and thus, can be delivered directly to the defect site to
stimulate host cell activity.
PRP was added to both unmodified and modified scaffolds during implantation to
further potentiate the osteoinductive effects on the host microenvironment. PRP
enhances the proliferation of mesenchymal stem cells in vitro (158-160) and has been
defined as an osteopromotive substance (4). Recombinant growth factor therapy,
although reportedly beneficial (26, 43, 45, 161), cannot replicate the complex milieu of
growth factor signaling that occurs with healing and bone development. Moreover, the
clinical use of recombinant human bone morphogenetic protein-2 (rhBMP-2) and
rhBMP-7 have shown signs of uncontrolled bone growth (27). Mesenchymal stem cells
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are receptive to growth factor signals produced in the host tissue and are necessary to
initiate the beginnings of bone healing (162); however, obtaining sufficient numbers can
prove challenging. While MSCs can be expanded in culture in preparation for
implantation, continued passaging of MSCs or the use of MSCs from aged donors can
lead to a loss of mitogenic and osteogenic potential (101-103). This is most likely
attributed to an increase in cell senescence and/or apoptosis (101, 103). Thus, the
benefits of including autologous PRP in the implant procedure was two-fold: (i) robust
enhancement of host progenitor cell numbers at the defect site without the need for
extensive subculturing of stem cells and (ii) replication of the complex signaling events
associated with healing and bone regeneration.

Evidence of bone regeneration after incorporation of these therapies was initially
investigated by radiological assessment of the defect site (Fig. 12). There was no
radiographic evidence that functionalization of CA with melatonin or the addition of PRP
enhanced defect site intensity more than the unmodified CA group; however, there was
an overall increase in radiographic intensity over time for all groups from three months to
six months (Fig. 12B). Initial histology of experiment groups provided some evidence of
scaffold degradation, although the overall integrity of the defect site was not
compromised out to six months (Fig. 14A). Taken together, these results suggest that the
degradation of CA scaffolds may be adequately balanced by bone formation. Indeed, a
decrease in radiographic intensity would likely indicate a rapid degradation of the
biomaterial without appropriate bone fill. Moreover, unbalanced rates of degradation and
bone tissue formation could compromise the integrity of the defect site.
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Just as the porosity of a biomaterial can dictate the extent of cellular migration
and tissue infiltration, porosity also exposes the biomaterial to the in vivo environment
and likely facilitates its degradation (124). The process of biodegradation and the degree
to which an implant is resorbed can have a large influence on the materials bone bonding
properties (124). Biodegradation of many of the bioactive ceramics occurs through either
solution-mediated or cellular-mediated processes. For example, calcium phosphate
materials like hydroxyapatite and β-TCP undergo simple dissolution to release free
calcium and phosphate ions (124). Likewise, the biodegradation of these materials can
also be attributed to phagocytosis by mesenchymal stem cells or giant cells (124).
Indeed, the various phases of CA (due to variations in Ca:Al ratios) can provide a method
for controlling the rate of ceramic dissolution (142, 155). It is possible that similar
biodegradation processes were occurring at the implant site during the current study, as
signs of particulate accumulation in the surrounding connective tissue are absent. Further
investigation of this phenomenon is warranted in future studies. Additionally, while
radiological techniques are routinely used to measure bone-defect repair, x-ray computed
microtomography enables 3D construction of the internal structure of small radio-opaque
objects (13). Thus, this technology may have valuable applications for the investigation
of qualitative and quantitative aspects of bone formation on and within CA scaffolds.

Radiographic analysis provided a limited analysis of bone formation and changes
in scaffold density at the implant site. Therefore, the presence and difference in bone
remodeling capabilities between experimental groups was assessed qualitatively and
quantitatively using a double fluorochrome labeling series. Fluorochromes, like
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oxytetracycline and calcein, are fluorescent labels with calcium affinity. The
incorporation of different fluorochrome injections at two different time points allows the
pattern and rate of calcium precipitation during mineralization to be visualized with the
aid of different wavelength filters.
Bone remodeling activity was significantly enhanced in defect sites treated with
modified scaffolds (Fig. 13). Specifically, the presence of melatonin on CA scaffolds
increased the degree, intensity, and abundance of bone remodeling activity at three and
six month time points compared to other experimental groups (Fig. 13B-D). These
findings suggest that modified scaffolds may significantly impact the mineralization of
osteoid tissue that adheres to the CA surface and further promote bone formation in vivo.
Increased bone remodeling activity may be a result of the effect of melatonin on
osteoblast differentiation and activity (57, 67, 68) including increasing the transcription
of genes implicated in remodeling processes such as Runx-2, Bmp-2, and osteocalcin (68,
72, 74) and increasing collagen type I synthesis (75). Based on the in vitro studies and
histology, the presence of melatonin on the scaffold surface does not appear to interfere
with the differentiation of hAMSCs into osteoblast or the migration of cells and the
infiltration of tissue from the defect border. On the contrary, it may actually enhance
these phenomena as a chemoattractant molecule (146).
More abundant sites of remodeling in the CA-Mel group support histological
findings and suggest cell migration to deeper aspects of the scaffold may have been aided
by an optimal pore size and interconnectivity (Fig. 13A). Specifically, these results
suggest that cell types associated with bone remodeling were capable of reaching and
functioning at interior portions of the CA biomaterial. Bone remodeling within a porous
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biomaterial is critical for the integration of the implant into the environment. Bone
remodeling located exclusively around the periphery of a porous implant would not
facilitate its fixation in the bone environment nor aid in the transmission of load-bearing
forces (124).
Despite the possibility of CA-induced hAMSC differentiation noted in vitro, these
results may not have translated to the in vivo model system or, conversely, may not be
adequate enough to stimulate all aspects of the bone remodeling process. Although the
average pore size of the unmodified CA material utilized in this study is sufficient for cell
migration and bone ingrowth (31), negligible bone matrix infiltration and bone
remodeling activity were observed (Figs. 13 and 14). Thus, efforts to enhance the
stimulatory effects of the implants on the host microenvironment may be required for
successful bone formation in vivo in calvarial defects as indicated by the benefits of CAMel groups.
Although CA-Mel implants significantly impacted bone remodeling in calvarial
defects, a non-significant effect of time was obtained (Fig. 14). In the future, in vivo time
points should be adjusted to determine the onset and duration of action of melatonin on
modified CA scaffolds. For example, if melatonin activity reaches a peak and is
maintained over time, time points prior to 3 months may be necessary to analyze this
effect. Conversely, if melatonin activity gradually increases over time, extended time
between each time point may be required to detect significant changes, such as 3, 8, and
13 month time points. These future modifications could determine whether the effects of
melatonin are early, exhibit only modest increases over 3 month periods, or are
maintained after a specific “window” of peak activity. Other collected data suggest that
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the organic acid modifiers (linkers) of the CA surface cannot be removed by chemical
(i.e., solvent rinses) or mechanical (i.e., sonication) means (134); however, future studies
should examine the stability of the immobilized melatonin over time by analyzing the
release of melatonin from the CA surface in culture. Evidence for melatonin release and
the pattern of its dissolution could be examined in exhausted cell media or simulated
body fluid by radioimmunoassay or HPLC methods. The lack of two distinct labels on
fluorescent micrographs may be due to the close proximity of the tetracycline and calcein
injections. As the injection series was based on a protocol for double labeling long
bones, it may need to be modified to include an increased time span between label
injections in future studies when working with calvarial defect models. Nonetheless,
visual evidence of fluorochrome incorporation supports bone remodeling activity is
occurring. Further, given that fluorescence around and through the scaffolds overlaps the
cells and proteins depicted by the histological stain, the quantified fluorescence is a
reliable predication of bone remodeling activity for the experimental groups.

Theoretically, the growth factors contained in PRP could have synergistic effects
on osteoprogenitor cell and osteoblast proliferation to improve bone formation and
integration (163). Despite containing over 30 biomolecules, many implicated in initiating
a variety of responses associated with bone healing (86), the inclusion of PRP in this
model of calvarial defects showed either negligible or inhibitory effects on bone
remodeling when used alone or in combination with melatonin, respectively for the time
points analyzed (Fig. 13). Specifically, combinations of PRP with CA-Mel scaffolds
reduced bone remodeling to control levels.
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Our findings seem consistent with other studies that have demonstrated that the
effects of PRP are transient and take place within a short period of time. This is most
likely attributed to the fact that the robust release of growth factors lasts for only the
lifespan of the platelets. Although age and gender do not appear to affect platelet
numbers or growth factor levels in PRP harvested from humans (164), variability of PRP
effects in animal models may be species-related or suggest differences in growth factor
signal responsiveness. Indeed, some report no effect of PRP on bone formation when
combined with stem cells, autogenous bone, or biomaterials (44, 84, 165, 166).
Interestingly, PRP produced greater effects on bone regeneration when applied to
metallic surfaces versus ceramic surfaces (163), suggesting that the chemistry of the
implant surface may affect the osteopromotive effects of PRP. Additionally, the rapid
coagulation of PRP over the CA implants may have occluded scaffold pores making it
difficult for host cells to migrate onto the scaffold surface and/or limiting bone ingrowth.
Although evidence of connective tissue infiltration was observed in histological sections
or PRP-treated implants, the conflict created between the proliferative signals of PRP and
the differentiation signals of melatonin may have delayed or attenuated the progression of
bone remodeling. While PRP enhances the proliferation of stem cells (118, 159, 167), it
either decreases (159) or does not affect (118, 160) their differentiation. Thus,
differentiation responses may be postponed to later time points and may correspondingly
delay osteoid mineralization. These physical and chemical barriers associated with PRP
application may explain the lack synergism between PRP and melatonin in vivo.
Interestingly, the combination of melatonin with fibroblast growth factor-2 enhanced
bone formation and facilitated osteointegration (168). This suggest that the
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differentiation signal may need to be the stronger of the two for adequate bone
regeneration. The effects of PRP on hAMSC differentiation and calcium deposition
requires closer examination of specific time points based on the results reported here.
The temporal regulation of growth factor signals at the site of implantation may be of key
importance and warrants further study.
Although some report the exogenous activation of PRP prior to its application
(94, 116), its activation can occur spontaneously under microenvironmental cues and is
required for the release of growth factors (85, 159). PRP prepared in this study was not
activated with either bovine thrombin or calcium chloride. Previous studies have shown
that growth factor levels through this preparation technique are similar to activated PRP
preparations (118). Activation with bovine thrombin and calcium chloride has been
shown to adversely affect growth factor levels (169) and may compromise bone healing
(170). Moreover, the use of bovine thrombin in humans can induce a robust immune
response, including the development of cross-reactive antibodies (171). Thus, it is
believed that microenvironmental cues were sufficient to activate PRP in the current
study without the need for activation by exogenous additives that may have compromised
bone formation.

FUTURE DIRECTIONS
The application of PRP to in vitro models needs to be further refined for future
studies. In the current study, the presence of residual cell types for extended periods of
time in culture and coagulation of PRP over scaffold surfaces complicated the analysis of
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PRP-treated groups. In the future, methods to further purify and concentrate the platelet
population should be considered. For example, differential centrifugation techniques
using a Histopaque®/PercollTM gradient could be used to separate platelets and peripheral
blood mononuclear cells (i.e., monocytes, lymphocytes, and macrophages) from
erythrocytes or to specifically concentrate the platelet population. Likewise, the
concentration of PRP may have significant implications on the cellular response to the
therapy. High concentrations (>10%) suppressed, while low concentrations (1 – 5%)
stimulated, the viability and proliferation of alveolar bone cells (172). Moreover,
researchers have suggested that the concentration of platelets in PRP required for a
desired biological effect in human subjects may vary between individuals (172). The
“therapeutic” target range for platelet concentration has been set at 5 times baseline
levels, approximately 1 million platelets/µL (81). Future studies should determine the
concentration of platelets needed to elicit regenerative responses in the models tested and
verify adequate concentrations of platelets are achieved prior to application. Platelet
concentration can be determined using manual or automated counting procedures. The
removal of clotted PRP from scaffold wells may have inadvertently disrupted or removed
the layer of hAMSCs. To circumvent this issue, culture plate membrane inserts could be
considered as a means of physically separating clotted PRP from the hAMSC layer while
still allowing the diffusion of growth factors (e.g., Minicell Cell Culture Inserts,
Millipore, Billerica, MA).

The main inorganic portion of bone is hydroxyapatite (Ca10(PO4)6(OH)2). In vitro
mineralization can be assessed using histochemical stains such as von Kossa or Alizarin
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Red S. Von Kossa stain reacts with the anionic portion of phosphates, carbonates, and
other salts (173) while Alizarin Red chelates with the calcium portion (174). Thus,
neither method is specific to the hydroxyapatite molecule. As such, the use of Alizarin
Red S in initial mineralization assessments was confounded by the calcium component of
CA scaffolds. Specifically, nonspecific binding made it difficult to differentiate between
the calcium component of the CA material and that of calcium deposits as a result of
mineralization. Moreover, the Von Kossa method is not quantifiable. In future
experiments, the assessment of in vitro mineralization may benefit from the use of
OsteoImage Mineralization Assay kits (Lonza, Walkersville, MD). These kits are
designed with a fluorescent probe that specifically binds the hydroxyapatite molecule in
mineralized nodules. Mineralization by this method can be assessed qualitatively using
fluorescence microscopy or quantitatively by plate reader methods.

Although in vitro assays contribute to the comprehension of biological
mechanisms, they are limited in their capacity to fully replicate the complex milieu of the
in vivo microenvironment. In order to achieve the clinical translation of bone tissue
engineering strategies, models should mimic the clinical and biological environment and
allow the success and functional performance of the regeneration to be assessed by
qualitative and quantitative methods (13). In an attempt to further define molecular
mechanisms of melatonin and PRP combinations in culture while replicating the host
microenvironment, co- and tri-culture experiments should be considered. Experiments
could be devised to examine the effect of osteoinductive components on the dynamic
relationship between osteoblasts, osteoclasts, and hAMSCs. Additionally, bioreactors
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can be utilized to provide biophysical stimulation, improve nutrient transfer, and enhance
functional assembly of cells cultured on scaffold materials (175). Interstitial flow
through a scaffold material can be replicated with a perfusion bioreactor and has been
shown to induce osteoblastic differentiation as well as extracellular matrix and calcium
deposition (175, 176). These culture conditions and devices could be valuable tools for
further studying the mechanisms of cell-scaffold interactions while approximating a
physiological environment.

Platelet-rich plasma is a growth factor-rich substance that promotes mitogenic
responses in vitro and in vivo. The additive or synergistic effect between PRP and
melatonin in the current study may be dependent on an appropriate separation of
proliferative and differentiative responses. Indeed, the temporal and spatial regulation of
growth factor release and activity is a common attribute of biological repair mechanisms
(81, 82). Future cell culture models should consider defining an appropriate “window”
between PRP application and melatonin exposure to optimize hAMSCs response for the
greatest differentiation and most robust calcium deposition. As platelets typically expire
within 5 -7 days (81), the development of a slow-release melatonin component to CA
scaffolds may sufficiently separate hAMSC exposure to the influences of PRP and
melatonin. While the immobilization of melatonin to the CA surface resulted in
significant osteoinductive improvements, there is little control over when cells and tissues
of the microenvironment are exposed to the molecule. Alternate drug delivery systems
could be designed to release agents at a specific rate over a specific period of time at the
desired location (130). Because the synthesis of CA scaffolds does not require high heat
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treatments to impart mechanical strength, the thermal degradation of the melatonin
component may be avoided.

The creation of an optimal grafting material typically centers around three
biological prerequisites for fracture healing: (i) suitable osteoconductive surfaces, (ii)
osteoinductive stimulation by growth factors, and (iii) viability and availability of
osteogenic cells (153). Although not considered in the current study, the influence of
osteogenic components on bone regeneration should be considered in future models. For
example, hAMSCs could be seeded and cultured on CA scaffolds prior to implantation in
defect models. This modification would be of substantial value given the reported effects
of modified scaffolds on hAMSCs and bone remodeling reported here and the effects of
exogenous melatonin administration on the differentiation of hAMSCs reported
elsewhere (67, 68). Porous hydroxyapatite and β-tricalcium phosphate scaffolds seeded
with allogenic MSCs demonstrated regenerative capacity comparable to autogenous
cancellous bone in large femoral defects in dogs (4). Additionally, the development of
tissue engineered temporomandibular joint constructs for craniofacial applications has
benefited greatly from the incorporation of MSCs (177). Finally, encouraging results
have been reported from clinical trials utilizing MSCs for the treatment of osteogenesis
imperfect and metachromatic leukodystrophy (5).

The quality and quantity of bone formation in osseous defects can be influenced
by the species of animal used, age of the animal, stability of the defect, anatomic
location, type of bone, and the presence or absence of periosteum (114). Given the
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challenges associated with regenerating bone in the calvarial model and in light of the
beneficial effects of modified scaffolds on bone remodeling reported here, equally or
more significant effects may be seen in models where impact forces facilitate bone
remodeling activity (e.g., femoral or tibial defects) and should be considered in the
future. These models could provide vital information regarding the utility of unmodified
and modified CA scaffolds for long bone injuries.

Finally, physical forces have been investigated in fracture healing and include
pulsed electromagnetic fields (PEMF) and pulsed ultrasound (low-intensity pulsed
ultrasound; LIPUS) (178, 179). Numerous authors have reported that these adjuvant
techniques have a positive effect on bone healing, specifically with regard to vertebral
and long bone injuries (179). A systematic review of the published clinical data on both
techniques revealed that LIPUS speeds acute fracture healing and promotes healing in
nonunion fractures (179). Application of physical forces to fresh fractures showed an
acceleration of healing by 30% and a 71% reduction in nonunion with 12 weeks after the
initiation of therapy (178). It is hypothesized that the strain-generated electrical
potentials may be a regulator signal for cellular processes of bone regeneration (178).
These methods may further enhance the bone forming potential of bioactive CA
therapies.
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CONCLUSION
The use of autogenous bone for grafting procedures is still a relevant clinical
practice given its naturally inherent bone regenerating capacity and histocompatability.
Nonetheless, donor site morbidities are prevalent concerns and the average cost of a
routine iliac crest bone graft harvest is estimated at $4200 including anesthesia and
hospital stay (180). Significant advances in the field of tissue engineering and
regenerative medicine have provoked scientists to evaluate the clinical utility of cheaper,
less invasive methods of bone grafting utilizing synthetic materials. Mimicry of native
bone physiology and mechanical properties, however, is a substantial challenge to these
endeavors.
The objective of this study was to create a bone regenerative substitute that more
accurately displays the bone regenerating properties of natural bone (e.g.,
osteoconduction and osteoinduction). The use of calcium aluminates for bone
replacement provides for an unlimited quantity and consistent quality of the graft material
while removing the need for autologous donor sites. It is a moldable, durable material
that may withstand the forces of weight-bearing or high-impact activity while limiting the
potential for implant site infection or material rejection. The unique combination of CA
scaffolds with melatonin has created a novel bioactive biomaterial with both
osteoconductive and osteoinductive potential. Slow degradation of the calcium aluminate
over time would best allow for the infiltration and integration of new bone matrix and
mature bone formation. Given the challenges associated with regenerating bone in this
model, equally or more significant effects should be seen in models where impact forces
facilitate bone remodeling activity. The use of this novel bioactive synthetic scaffold has
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the potential to change the dogma of bone grafting in several fields including dentistry
and reconstructive surgeries. The clinical use of this technology has the potential to
significantly reduce the cost and complications associated with bone graft procedures,
reduce the time patients spend in recovery, and reduce or eliminate the need for
revisional surgeries. Continued research and optimization of this therapy is warranted
and the attachment of other biomolecules that facilitate cell adhesion and combat
infection have been considered (50, 105).
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APPENDIX

Unmodified Calcium Aluminate – Day 7; n =3
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Unmodified Calcium Aluminate – Day 14; n =3
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Modified Calcium Aluminate (CA-Mel) – Day 7; n =3
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Modified Calcium Aluminate (CA-Mel) – Day 14; n =3
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